2022
年度報告
2
4
8
53
151
152
185
193
255
285
290
398
403
1 2022
Margaret Han Dugan 3
Ranjeev Krishana
Donald W. Glazer
Michael Goller
Anthony C. Hooper
Alessandro Riva 1
Margaret Han Dugan 1
Donald W. Glazer
Michael Goller
Anthony C. Hooper ** Alessandro Riva 4
Ranjeev Krishana Margaret Han Dugan 1
Thomas Malley Michael Goller
Alessandro Riva 1
Thomas Malley
Corazon (Corsee) D. Sanders Corazon (Corsee) D. Sanders
Thomas Malley Anthony C. Hooper
Anthony C. Hooper Margaret Han Dugan 2
Corazon (Corsee) D. Sanders Ranjeev Krishana
Corazon (Corsee) D. Sanders
* 2022 1 31
2022 6 22
** Anthony C. Hooper 2023 4 17 2022 12 31
2023 4 16 Anthony C. Hooper
2022 2
(FCG, HKFCG)
Vistra Corporate Services (HK) Limited
Mourant Ozannes
183
Ernst & Young LLP
17 1712-1716
Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Mourant Governance Services Grand Cayman KY1-1108
(Cayman) Limited Cayman Islands
94 Solaris Avenue
Camana Bay
Grand Cayman KY1-1108
Cayman Islands 06160
www.beigene.com
1. 2022 2 1
2. 2022 2 25
3. 2022 9 13
4. 2022 2 1 2022 11 20
3 2022
2022 4
5 2022
ADS
2022 6
7 2022
3
(BTK)
PD-1
PARP1 PARP2
13
2,700
50 80
30
3 18,000
CMO
2010 29
9,000
2022 8
( )
NASDAQ: BGNE;
HK: 06160; SSE:
BeiGene (Hong Kong) Co.,
BeiGene UK, Ltd.
Limited
( )
( )
( ( )
( )
)
(
)
9 2022
12
1. 950
14
3
(CLL) (PFS) (ORR)
BCL-2
BGB-11417 HPK1 BGB-15025 BTK
(CDAC) BGB-16673 OX40 LAG-3 TIM-3
CDAC ADC CAR-NK mRNA
2. 2,300
(CRO) 75%
2022 10
3.
29 35 4,800
800 ALPINE
BTK 2022 (ASH)
BCL-2
PD-1
PD-1/PDL-1
OX40 TIGIT LAG-3 TIM-3
4. 3,500
BTK PD-1/PDL-1
13
65
5.
2023
11 2022
2023 2 27
CLL/SLL R/R BTK
MCL WM R/R MZL
1 1
65
R/R MCL2 R/R CLL/
SLL2 R/R WM2
3
WM R/R MZL
R/R CLL/SLL
1L NSCLC PD-1
2/3L NSCLC R/R BLA
2
2/3L HCC 2
MAA4
R/R PD-L1+ UC 2
MSI-H dMMR
2L ESCC 1L NPC
1L GC/GEJC
3L BRCA 2
PARP
8
RANK
(SRE) 8
R/R 8
CD19 CD3
T (BiTE)
R/R 8
2022 12
R/R
DNA
Castleman IL-6
2
GD2
VEGF
5
BRAF 7
5
MEK 7
VEGFR 7
6
mTOR 7
ALK NSCLC ALK 7
13 2022
1. 2.
3.
(EU) 27 4.
(ESCC)
(ESCC) (NSCLC) 5.
(NSCLC) 6. (VEGF)
7.
8.
ALK= BLA= BRAF=B
CLL= EGFR= ESCC= GC= GEJC=
HCC= MAA= MCL= MEK=
mTOR= MZL= NPC=
NSCLC= R/R= SLL= UC= VEGFR=
WM=
zanubrutinib BTK BTK
BTK
2022 14
2019 11 (MCL)
(WM) CD20
(R/R) (MZL) MCL MZL
2023 1
(FDA) (CLL) (SLL)
(EC)
WM MZL CLL
MCL
CLL SLL R/R WM (NMPA)
CLL SLL WM sNDA 2021 12
R/R WM NSHA
NRDL
2023 2
65
15 2022
(NHL) (HL)
2022 BTK 85 2026 BTK
200
tislelizumab 1(PD-1)
IgG4 Fcγ (FcγR)
T
(NSCLC)
NSCLC
NSCLC
(ESCC) (NPC) PD-L1
(NMPA)
(cHL) PD-L1
12 (UC)
(HCC) (MSI-H) (dMMR)
2020
cHL UC NRDL 2021 NSCLC NSCLC 2/3L HCC NRDL
2022 NSCLC MSI-H
ESCC (NPC) NRDL
2022 16
NMPA (CDE) 2
(sBLA)
(HCC)
17 13 3 4 2
2021 1
FDA
ESCC (BLA)
2022 PD-1/PD-L1 360 2022 PD-1/L1
22
2025 500
17 2022
pamiparib 1(PARP1) PARP2
PARP-DNA
1,300
2021 5
BRCA(gBRCA)
2021
XGEVA denosumab RANK (RANKL)
(MM) (SRE)
(GCTB)
70
2019 5
GCTB 2020 11 SRE 2020 7
2020 12
GCTB 2023
BLINCYTO blinatumomab CD-19 CD3 T
T (BiTE) 60
(ALL)
2020 12
ALL 2022 4 B
2021 8
KYPROLIS carfilzomib 60
(MM)
2021 7 R/R MM
2022 1
2023 3
2022 18
REVLIMID lenalidomide 2013
(MM) 2018 2
NMPA
MM
2017 6
2019 11
2020 11 NMPA
VIDAZA azacitidine DNA
2017 4 -2
(MDS) (CMML) 20% 30% (AML) 2018 1
ABRAXANE 2020
3 ABRAXANE
2020 3 25 NMPA
ABRAXANE
2021 10 180 ABRAXANE
ABRAXANE
ABRAXANE
EUSA Pharma
SYLVANT siltuximab -6(IL-6)
(HIV) -8(HHV-8) Castleman (iMCD)
2021 12 (HIV) -8(HHV-8)
Castleman (MCD) MCD(iMCD)
19 2022
QARZIBA β dinutuximab beta GD2 NMPA
12
(R/R)
2021 12
(BAT1706)
NSCLC
2021 11 NMPA 2021 NSCLC
2020 11
EMA FDA BLA
2022
60
2022 20
14 95%
2017
2022
2023 1
2023 3 1
9
(EGFR) (ALK)
(NSCLC)
EGFR ALK
NSCLC 2022 1 2023 NRDL
(MSI-H) (dMMR)
2022 3
2023 NRDL
21 2022
2022 4 2023 NRDL
2022 6 2023 NRDL
(EGFR)
(ALK) 2021 6
2021 NRDL
(HCC) 2021 6
2021 NRDL
2021 1 2021 NRDL
PD-L1 12
(UC) 2020 4 2020 NRDL
2 (cHL) 2019 12
2020 NRDL
2022 22
3
(WM) 2021 6
2021 NRDL
(MCL) 2020 6
2020 NRDL
(CLL)
SLL) 2020 6 2020 NRDL
BRCA(gBRCA)
2021 5 2021 NRDL
2023 3 1
2
2023 3
2020
NRDL
23 2022
2017
2019
2018 2020
2018
4+7 11 2018 2019
(Medicare) (Medicaid)
(PBM)
myBeiGene
(Co-Pay)
2022 24
2023 2 27
R/R
(CLL)
(SLL)
(MCL) R/
+
R (MZL)
BTK
+/- Bcl-2
(CLL)
(SLL)
+ CD20 R/R (FL)
2L
(ESCC) 1L (HCC)
2L/3L (NSCLC)
(HCC)
R/R
(cHL)
1L
(ESCC) 1L (GC)
PD-1 +
(GEJC) 1L
(NPC)
+ zanidatamab HER2
1L (GEA)
+
+ sitravatinib RTK 2L (NSCLC)
+ (VEGFR)*
1L PD-L1
(NSCLC)
+ 2L PD-L1+
(ESCC)
2/3L
(TIGIT) + + 1L (NSCLC)
PD-L1+
+ + (NSCLC)
1L
(SCLC)
25 2022
Surzebiclimab + + -
BGB-A425 TIM-3 LBL-007 LAG-3
BGB-A445(OX40) +
+
B
+
BGB-10188(PI3K)
B
+
BGB-15025(HPK1) +
1L
(GC)
PARP 1/2
+
BRAF
BGB-3245(BRAF)
+ mirdametinib MEK
Lifirafenib(RAF)
R/R (MCL)
R/R
(CLL)
(SLL)
B
BGB-11417(Bcl-2) +
+ +
+ + t(11:14) R/R
(MM)
BGB-16673 (BTK B
CDAC)
BGB-23339(TYK2)**
BGB-24714 SMAC
+
^
BGB-B167 CEA x
+
4-1BB
cHL= CLL= ESCC= FL= GC=
GEA= GEJC= HCC= MCL= MZL= NPC=
NSCLC= R/R= SCLC= SLL= TN=
2022 26
2023 2 27
Sotorasib
(CRC)
(NSCLC)
tarlatamab^^ (SCLC)
acapatamab ^^
(NSCLC)
AMG 176
AMG 427^^ (AML)
AMG 509
AMG 199^^ (GC)
(GEJC)
AMG 650
AMG 256
Sitravatinib+ (NSCLC)
Sitravatinib+ (HCC)
(GC)
(GEJC)
Sitravatinib +
Zanidatamab + (GEA)
+
Zanidatamab (BTC)
Zanidatamab (BC)
(GC)
(GEA)
ZW49 HER2
BGB-32451
SEA-CD70
(MDS)
(AML)
DKN-01 + (GC)
+ (GEJC)
LBL-007 +
ABI-H3733
^ BiTE ^^ BiTE XmAb Xencor Mirati sitravatinib
(NSCLC) 3 SAPPHIRE ZW25 1 MapKure
SpringWorks Therapeutics
AML= BC= BTC= CRC= GC= GEA= GEJC=
HCC= MDS= NSCLC= SCLC=
27 2022
SEC
BTK
B
24 BTK
BTK BTK
2022 12 5 26
Adium Pharma NewBridge Pharmaceuticals
Erkim Nanolek Medison
10 10 5 3 5
2
2022 28
WM 3 ASPEN NCT03053440
CLL/SLL 3
SEQUOIA NCT03336333 CLL/SLL 3
ALPINE NCT03734016 CLL 3
MCL 3 (NCT04002297) 3
FL MZL 3 (NCT05100862)
2 MCL
WM CLL/SLL NCT03206970 NCT03332173 NCT03206918
MZL MAGNOLIA NCT03846427
FL 2 ROSEWOOD NCT03332017 2022
(EHA) ROSEWOOD
MCL MZL CLL/SLL CLL/SLL
2023 1 2022
11 CLL/SLL
10
PD-1
PD-1
21 13 3 4 2
29 2022
NSCLC 3
(NCT03358875)
NSCLC 3
NCT03594747 NCT03663205
SCLC 3 (NCT04005716)
NSCLC 3 (NCT04379635)
HCC 3 (NCT03412773)
HCC 2 (NCT03419897)
3
(NCT03777657)
(cHL) 3
(NCT04486391)
cHL 2 (NCT03209973)
2022 30
3 (NCT03967977)
2 (NCT04004221)
ESCC
ESCC 3 (NCT03430843)
ESCC 3 (NCT03783442)
ESCC 3
(NCT03957590)
MSI-H/dMMR 2 (NCT03736889)
3
(NCT03924986)
2022 12 31 11,000
4,000 11
31 2022
PARP1 PARP2
pamiparib 1(PARP1) PARP2
DNA PARP
2021 5
BRCA(gBRCA)
3
(NCT03519230) 2 (NCT03427814)
1b (NCT03150810)
(BGB-A1217) TIGIT
(BGB-A1217) TIGIT IgG1
3 NSCLC AdvanTIG-
301(NCT04866017) AdvanTIG-302(NCT04746924) 2022 12
1,600 8
2021 12
Ociperlimab
AdvanTIG-202 (NCT04693234)
2023 2
2022 32
Lifirafenib(BGB-283) BGB-3245 RAF
Lifirafenib RAF Lifirafenib
BRAF V600E V600E BRAF KRAS/NRAS
lifirafenib (MAPK) BRAF BRAF
KRAS/NRAS lifirafenib
NSCLC
SpringWorks Therapeutics(SpringWorks) 1b
(NCT03905148) lifirafenib SpringWorks MEK mirdametinib(PD-0325901)
SpringWorks MapKure, LLC
RAF BGB-3245 MapKure BGB-3245 v-RAF
B(B-RAF) 1 (NCT04249843)
Sitravatinib
2018 1 Mirati Therapeutics, Inc(Mirati) Mirati sitravatinib
Sitravatinib
RET TAM TYRO3 Axl MER
VEGFR2 KIT Mirati sitravatinib
2019 sitravatinib NSCLC 3 SAPPHIRE 2022
Mirati sitravatinib PD-L1
ESCC 2 (NCT05461794)
33 2022
sitravatinib NSCLC 3
(NCT04921358)
BGB-11417 Bcl-2
BGB-11417 Bcl-2 BGB-11417 (IND)
Bcl-2
Bcl-xL Bcl-2
2022 ASH
CLL (AML) (MM) 1 NCT04883957 NCT04277637
NCT04771130 NCT04973605 2022 BCL-2 BGB-11417
(NCT05471843) CLL/SLL (NCT05479994) 2
2023
BGB-A445 OX40
BGB-A445 OX40 BGB-A445 OX40
OX40 BGB-A445
BGB-A445 TLR9
PI3Kδ sitravatinib BGB-A445
1 (NCT04215978) 2022 1 (NCT04215978)
(NCT05661955)
2022 34
ZW25(zanidatamab) HER2
Zanidatamab AzymetricTM HER2
Zymeworks Inc.
zanidatamab zanidatamab HER2
1/2 (NCT04215978) zanidatamab
zanidatamab PD-1 zanidatamab
HER2 (BTC) 2b HERIZON-BTC-01(NCT04466891) 2022
2021 3 (NCT05152147)
zanidatamab HER2 2022 2L
Surzebiclimab(BGB-A425) TIM-3
S u r z e b i c l i m a b ( B G B - A425) T -3( T I M -3) I g G1
surzebiclimab 1/2
(NCT03744468)
BGB-15025 HPK1
BGB-15025 HPK1 HPK1 TCR
HPK1 T BGB-15025
2021 BGB-15025
1 (NCT04649385) 2023 BGB-15025
BGB-16673 BTK CDAC
BGB-16733 BTK (CDAC) BTK
BGB-16673 BTK BTK BTK
BTK (R/R)B
1 (NCT05006716)
35 2022
BGB-23339 TYK2
BGB-23339 2(TYK2) TYK2 JAK
BGB-23339
TYK2 (JH2) (IL)-12
IL-23 1 (IFN) BGB-23339 1
(NCT05093270)
BGB-24714 SMAC
BGB-24714 (SMAC) BGB-24714
1 (NCT05381909)
BGB-B167 CEA 4-1BB
BGB-B167 CEA 4-1BB BGB-B167
CEA (CRC) 1
(NCT05494762)
BGB-10188 PI3K
BGB-10188 PI3Kδ
1 (NCT04282018)
2022 36
10
60
12
(CMO)
CMO
(cGMP) cGMP
37 2022
13,000 1
2 x 500
6 50,000
100,000
2019 9 2020 12 24,000
54,000 2023 10,000 64,000
42
95 100
2022 38
CMO CRO
Catalent Pharma Solutions,
LLC(Catalent) Catalent
(API)
CMO
30
39 2022
CRO API
30 60
2019 10 31 BeiGene Switzerland GmbH
2020 1 2
2022 40
12.5
LUMAKRAS (Sotorasib)(AMG510)
AMG510
AMG 510
2023 2 (i) 2023 1 1 2023 8
31 AMG 510 (ii) AMG 510
41 2022
2019 10 31
2020 1 2 15,895,001
206,635,013 20.5% 27.8
13.45 174.85
(1) (a) (b) (c)
(2) 5%
(3) (a) (b)
(1) (2)
12 5%
20.6%
2022 42
2020 3 17
2020 9 24
20.6%
20.4% (1)
(2)
2020 12 1 (a)
20% (b) 60
(c)2023 12 1
2021 1 11
2021 2 26 Novartis Pharma AG
6.5
13 2.5
43 2022
(i)
(ii) PD-1 (Spartalizumab) BLA
Spartalizumab
120
180
2022 44
Ociperlimab
2021 12 19
TIGIT ociperlimab
3 2023
2023 6 7
7.45 11.5
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab
ociperlimab 50%
25%
ociperlimab
ociperlimab ociperlimab
45 2022
ociperlimab
120 ociperlimab
180
(1)
(2) (Hart-Scott-Rodino
Antitrust Improvements Act)
2017 7 5
2017 8 31
ABRAXANE
2020 3 25 NMPA ABRAXANE
2021 10 180
ABRAXANE ABRAXANE
ABRAXANE
2022 46
10
2023 1 30 48 32
PCT
PCT
FDA
FDA
47 2022
2023 1 30
1
2034
2034
B 2034
2037
2034
2033
2033
2033
2033
2033
2033
2033
2033
2033
2033
2031
2031
2031
2031
2036
2038
2031
2031
2036
2038
(1)
2022 48
BMS 2023 1 30
2023
2023
2023
2023
2023 1 30
2022
2029
2025
NMPA
49 2022
20
FDA
FDA 14
BeiGene
BeiGene
2022 50
CD20 B
BTK
BTK
2013 FDA
MCL 90
BTK CALQUENCE (acalabrutinib)
2017 FDA
MCL 2019 11 CLL/SLL 2023
1 27 FDA JAYPIRCA pirtobrutinib BTK
BTK R/R MCL
2017
2020
–FDA PD-1 PD-L1
BMS
BAVENCIO LIBTAYO
JEMPERLI
PD-1 PD-L1
2023 2 1 PD-1
H
PD-L1
Akeso PD-1xCTLA-4
(cadonilimab)
40 PD-1 PD-L1
51 2022
PARP 2018 8
2019 12 NMPA
2020 12
TIGIT Agenus Arcus
Compugen iTeos Therapeutics Mereo Biopharma Seagen
TIGIT 3
2022 52
53 2022
.
2017
2019 10
2019 2020 2021
2022 54
.
55 2022
.
Medicare
Medicaid
(Centers for Medicare and Medicaid Services, CMS)
CMS
2022 56
FDA
57 2022
2022 58
59 2022
2022 60
61 2022
(IRB)
CRO
GMP
IRB
2022 62
NMPA
63 2022
2020 3 25 NMPA
ABRAXANE
ABRAXANE
ABRAXANE
(Federal Anti-Kickback Statute)
(Federal False Claims Act)
2003 4
(April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical
Manufacturers)
2022 64
Medicare Medicaid
65 2022
340B FSS
Tricare
CMS
340B
340B
340B
340B
D
FSS Tricare
FCA
2022 66
340B
340B
340B
340B
FDA
FDA FDA
FDA
(NMPA) (EMA)
67 2022
FDA NMPA EMA
2022 68
2022 6
2023 1
2022 7 FDA
(ESCC) FDA
FDA
FDA
FDA
2020 3 FDA
FDA
FDA
FDA
69 2022
FDA
FDA
FDA IND (i) GCP
(ii)FDA
FDA (i)
(ii) (iii) FDA
FDA FDA
FDA
FDA
FDA
2022 70
FDA NMPA EMA
2020 3 25 NMPA
ABRAXANE
ABRAXANE
ABRAXANE
FDA NMPA EMA
FDA
NMPA EMA
71 2022
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA
NMPA EMA
2022 72
2022
FDORA FDA
FDORA FDA
FDA
FDA
73 2022
FDA
2020 1 ABRAXANE
ABRAXANE
2020 3 25 NMPA ABRAXANE
ABRAXANE
2020 8
2022 74
Hatch-Waxman
FDA
FDA
30
2020
NMPA
(NIPA)
AE
75 2022
SAE
SEC
AE SAE
IRAE
(REMS)
2022 76
2022 8 2022 (Inflation Reduction Act of 2022)
D
2,000 D
B D
77 2022
(Affordable Care Act)
2017 2021
2022 12 31 71
12.5
2022 78
2022 2021 2020 12 31 15 13
13 2022 2021 2020
20 15 16 2017
2017 9 2019
12
79 2022
2022 80
2022 12 31 39 550 6.653
2022 12 31
81 2022
18
2022 82
(USPTO)
83 2022
2022 84
FDA ANDA
ANDA ANDA
FTC
ANDA ANDA FTC
85 2022
2022 86
2023
2024
2027
PARP 2027 2031 TIGIT PD-1
ociperlimab 2034
87 2022
FDA
2022 88
89 2022
Catalent Pharma Solutions, LLC Catalent
2022 90
FDA
91 2022
2020 3 25 NMPA ABRAXANE
ABRAXANE
ABRAXANE
2022 92
2017 8
ABRAXANE 2020 3 25 NMPA
ABRAXANE
ABRAXANE
ABRAXANE
2019
2021 1 (Novartis Pharma AG)
PD-1
2021 12
TIGIT ociperlimab
2017
2019 6 2021 10 ABRAXANE
93 2022
(i)
(ii) (iii)
2022 94
95 2022
GMP
2020 3 25 NMPA
ABRAXANE
ABRAXANE
ABRAXANE
2022 96
HGRAC
2020 2022 KRAS G12C LUMAKRAS (sotorasib)(AMG510)
HGRAC
AMG 510
2023 2 (i) 2023 1 1 2023 8 31
AMG 510 (ii) AMG 510
HGRAC
97 2022
*
2022 8,000 9,000 15%
2022 98
99 2022
2019
2022 100
2022
7 7 2022 9 1
HGRAC NMPA
2021 3 1
2021 4 15
101 2022
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
FDA NMPA EMA
2022 102
103 2022
1934
2002
404
2022 104
2020 1 206,635,013
20.5%
(i) (ii) (iii)
2022
6 2022 8 1
105 2022
2020 2
2022 106
107 2022
2022 108
109 2022
PIPL
2022 110
PIPL
PIPL
2022 9
111 2022
2022 9 1
100
1 1 10 1
2023 3
2022 112
2022 2 15
1 31
113 2022
PIPL
PIPL
PIPL
5,000 5% PIPL
PIPL
2022 114
2019
115 2022
FDA
FDA
FDA
2022 116
117 2022
2022 118
2017
LIBOR 2021 LIBOR
LIBOR 2020 11 30
2021 12 31 LIBOR 2023 6 30 LIBOR
LIBOR LIBOR
LIBOR LIBOR
119 2022
OECD/G20
(BEPS)
2020 2019 1 1
2.0 2019 4 30
2019 1 1 2019 7 1
2019 1 1
2022 120
121 2022
2021 7
2021 7
VIE 2023
2 17 5
2023 3 31
ADS
2022 122
2023 2 24
2023 3 31
123 2022
10-K
2014
2021
Holding Foreign Companies Accountable Act HFCAA 2020 12
2021
2022 3 30
10-K
2022 3 8
2022 12 Accelerating Holding Foreign Companies Accountable Act
AHFCAA
2022 124
Ernst &Young LLP
2022 12 31
2022 8 26
2022 9 11 2022 12
Ernst & Young LLP
Ernst & Young LLP
2021 10
125 2022
2012
2014
2015
2014 2021
Ernst &Young LLP
2022 12 31
2022 126
1979
2020 1
2021 1 18
127 2022
2020 3
2022 128
2023 2 17
5 2023 3 31
3
3
129 2022
2022 130
2020 12 2021 1 18
131 2022
10% 50%
2022 12 31 35
2016
2022 132
10%
25% 5%
BeiGene (Hong Kong) Co., Ltd.
2010 11 22
(i) (ii)
(iii) (iv)
133 2022
25%
10%
20%
10% 20%
2022 134
25%
10%
135 2022
2022 136
137 2022
2022 138
ADS BGNE 06160
688235 ADS
2023 2 14 1,356,140,180 0.0001 863,876,312
66,452,024 13 115,055,260
139 2022
2020 5 11 S-3
300,197,772 17,297,026 224,861,338
2022 140
141 2022
2022 142
21
14
143 2022
\
2022 144
2021 12 15
1933
145 2022
2022 146
2018
0.2% 0.1%
147 2022
2022 148
2023 2 14 55%
(1) 75% (2) 50%
(PFIC) 2022 12 31
(Internal Revenue Service)
149 2022
F
50% 50%
10% 10% 1986
(Internal Revenue Code of 1986)
2022 150
12 31
2018 2019 2020 2021 2022
130,885 222,596 308,874 633,987 1,254,612
67,335 205,616 – 542,296 161,309
198,220 428,212 308,874 1,176,283 1,415,921
169,515 357,022 238,217 1,011,377 1,129,446
689,829 943,586 1,618,194 1,438,588 1,961,037
674,033 950,578 1,628,591 1,457,816 2,003,815
673,769 948,628 1,624,974 1,457,816 2,003,815
(%) 86% 83% 77% 86% 80%
(%) -340% -222% -527% -124% -142%
12 31
2018 2019 2020 2021 2022
740,713 620,775 1,390,005 4,382,887 3,875,037
1,068,509 364,728 3,268,725 2,241,962 665,251
1,697,390 862,384 3,885,491 6,014,325 3,738,550
2,249,684 1,612,289 5,534,795 8,535,525 6,379,290
496,037 633,934 1,731,514 2,402,962 1,995,935
14,445 16,150 – – –
1,753,647 978,355 3,803,281 6,132,563 4,383,355
(1) 10-K
151 2022
3
(BTK)
PD-1
PARP1 PARP2
13
2,700
50 80
30
3 18,000
CMO
2010 29
9,000
2022 152
2023 2 24 NMPA
PD-L1
(G/GEJ)
2023 1 19 FDA
(CLL) (SLL)
2023 1 19 (MHRA)
CLL
CD20 (MZL)
2023 1 18 PD-1
2022
RANKL
2023
3 1
2022 12 30 NMPA (CDE)
(HCC) (sBLA)
2022 11 17 (EC)
(TN) (R/R)CLL
2022 11 10
(WM)
CD20 (R/R)MZL
153 2022
12
1. 950
14
3
(CLL) (PFS) (ORR)
BCL-2
BGB-11417 HPK1 BGB-15025 BTK
(CDAC) BGB-16673 OX40 LAG-3 TIM-3
CDAC ADC CAR-NK mRNA
2. 2,300
(CRO) 75%
2022 154
3.
29 35 4,800
800 ALPINE
BTK 2022 (ASH)
BCL-2
PD-1
PD-1/PDL-1
OX40 TIGIT LAG-3 TIM-3
4. 3,500
BTK PD-1/PDL-1
13
65
5.
2023
155 2022
2021 1
(1)
(2)
2022 156
2021 12
TIGIT
5
(1) (2)
(3)
157 2022
(CROs) CMOs
2022 158
BTK
PD-1
TIGIT
PARP1 PARP2
BGB-15025 1(HPK1)
BGB-11417 Bcl-2
BGB-A445 OX40
BGB-16673 BTK CDAC
BGB-A425 TIM-3
BGB-10188 PI3Kδ
BGB-23339 2(TYK2)
LBL-007 LAG-3
Mirati Therapeutics, Inc. Mirati
ZW25(Zanidatamab) ZW49 Zymeworks Inc. Zymeworks HER2
(BAT1706)
159 2022
2022 160
161 2022
2021 12
2022 162
2022 2021 12 31
2022 2021 12 31
12 31
2022 2021 %
1,254,612 633,987 620,625 97.9%
161,309 542,296 (380,987) (70.3)%
1,415,921 1,176,283 239,638 20.4%
286,475 164,906 121,569 73.7%
1,640,508 1,459,239 181,269 12.4%
1,277,852 990,123 287,729 29.1%
751 750 1 0.1%
3,205,586 2,615,018 590,568 22.6%
(1,789,665) (1,438,735) (350,930) 24.4%
52,480 (15,757) 68,237 (433.1)%
(223,852) 15,904 (239,756) (1,507.5)%
(1,961,037) (1,438,588) (522,449) 36.3%
42,778 19,228 23,550 122.5%
(2,003,815) (1,457,816) (545,999) 37.5%
163 2022
2021 12 31 12 2022 12 31 2.396
14
6.50
2022 2021 12 31
12 31
2022 2021 %
1,254,612 633,987 620,625 97.9%
– 484,646 (484,646) (100.0)%
46,822 53,671 (6,849) (12.8)%
104,994 3,979 101,015 2,538.7%
9,493 – 9,493
161,309 542,296 (380,987) (70.3)%
1,415,921 1,176,283 239,638 20.4%
12 31
2022 2021 %
564,651 217,987 346,664 159.0%
422,885 255,119 167,766 65.8%
79,049 70,065 8,984 12.8%
63,398 45,956 17,442 38.0%
38,124 1,353 36,771 2,717.7%
36,107 12,515 23,592 188.5%
15,213 19,591 (4,378) (22.3)%
13,696 – 13,696
5,460 3,661 1,799 49.1%
16,029 7,740 8,289 107.1%
1,254,612 633,987 620,625 97.9%
2022 164
2022 12 31 13 6.34
2021 8
2022
(NRDL)
NRDL
2022 12 31
5.647 159.0% 2022 12
31
3.897 1.157 237.0%
MCL WM MZL 2022 12 31
1.503 48.6% CLL SLL
2022 12 31
4.229
65.8% 2022 12 31
2021 3 2022 1 NRDL
2021
4,560
2021 12 31 5,750
2021 3 1 NRDL
2022 1 1 NRDL NRDL
2021 12 31
NRDL NRDL
2022 12 31 1.613
2022 12 31 4,680
1.05
950 2021 12 31 5.423
4.846
2021 12 31 5,370
400 4
165 2022
2021 12 31 1.649 2022 12 31 2.865
2021 8
2021 12 31 4.691 2022 12 31
9.681 74.0%
2022 12 31 77.2%
2021 12 31 15 1.813 12.4% 2022 12 31
16 2022 2021 12 31
12 31
2022 2021 %
469,497 477,761 (8,264) (1.7)%
68,665 83,500 (14,835) (17.8)%
1
98,955 115,464 (16,509) (14.3)%
637,117 676,725 (39,608) (5.9)%
1,003,391 782,514 220,877 28.2%
1,640,508 1,459,239 181,269 12.4%
1. 2022 12 31 1.954 9,900
9,640
2022 166
2022 12 31
CRO
2.209 28.2% 10
1.147
5,760
4,760
2,500
2,400
2021 12 31 9.901 2.877 29.1% 2022
12 31 12.779
1.764
4,600
3,750
167 2022
2,780
2021 12 31 1,580 6,820
433.1% 2022 12 31 5,250
2021
2021 12 31 1,590 2.398
2022 12 31 2.239 2022 12 31
2022 12 31 4,280 2021 12 31 1,920
2022 12 31
2017 (IRC) 174
2022 1 1
2022 12 31 (1) 17
(2) 190 28 (3)
44.8
2022 168
2021 12 31 483.1 64.2% 2022 12 31 173.2
3.0
2021 12 31 242.6 16.4% 2022 12 31 282.3
2021 12 31 270.2 19.8% 2022 12 31
216.6 (1) (2) (3)
2021 12 31 587.6 44.0% 2022 12 31 845.9
2022 12 31 2021 12 31 294.8
262.4
169 2022
12 31
2022 2021
3 290,284 257,977
3 6 2,570 3,210
6 1 1,379 1,110
1 548 103
294,781 262,400
2022 12 31 2021 12 31
12 31
2022 2021
184,775 139,966
139,168 213,922
51,806 71,560
18,815 45,661
41,817 59,639
30,971 27,307
467,352 558,055
2021 12 31 558.1 16.3% 2022 12 31
467.4 (i)
(ii)
2022 170
2022 12 31
12 31
2022 2021
3,875,037 4,382,887
665,251 2,241,962
538,117 629,678
2022 2021 12 31
20 15 2022 12 31 71
2017 9
2022 12 31
12
2021 12 15
192.60
391.68 115,055,260
34
171 2022
2021 1
6.5 2021 12
TIGIT
2022 1 3
2022 2021 12 31
12 31
2022 2021
4,382,887 1,390,005
(1,496,619) (1,298,723)
1,077,123 640,659
(18,971) 3,636,911
(69,383) 14,035
(507,850) 2,992,882
3,875,037 4,382,887
2022 12 31 15 20
2.239
3.748 1.324
2022 172
2021 12 31 13 15
1.183 2.774
2022 12 31 11 16
3.254 1.437 1,590 150
2021 12 31 6.407 21
2.629 4,340 4,350 850
31
2022 12 31 1,900 4.171
3.138
4,700 3,740
2021 12 31 36 2021 12
34 4.064
9,280 5,000
1,680 3.218
173 2022
2021 12 15 217
SEC
2020 5 SEC
2022 174
2022 12 31
63,024 26,278 36,746
117,293 74,449 42,844
538,117 328,969 209,148
45,947 16,632 29,315
595,702 231,697 364,005
16,000 7,000 9,000
22,327 5,829 16,498
7,760 2,553 5,207
404,914 404,914 –
1,811,084 1,098,321 712,763
2022 12 31 1.173
5,530 BMS 6,190 BMS
175 2022
3.290 2.091
16
12.5
2022 12 31
6
1,900 2022 12 31
1,600
2022 12 31
2,230
2022 12 31
260
2022 176
2022 12 31 4.049
42
7,520
2
177 2022
NRDL
2022 178
179 2022
2
2022 12 31 2021 12 31 39 44
550 720 7 22
2022 12 31
2022 180
100 2022 12 31 210
210
2022 12 31 2021 12 31 1.732 4.831 2021
12 31 3
1994
(PBOC)
181 2022
2005
2022 2021 12 31 8.2% 2.3%
2022 12 31
2022 12 31
2021 12 31 10.3% 12.3%
2022 182
2022 12 31
2022 12 31 75.2
42
2022 12 31
2022 12 31
9,000 2021 12 31 8,000
2022 12 31 14 2021 10
183 2022
2022 12 31 5.5 2021 12 31
7.2 123.9
2021 12 31 145.8
2022 12 31 2021 12 31
2022 12 31
2022 184
11
2023 4 18
55
60
Margaret Han Dugan 66
Donald W. Glazer 78
Michael Goller 48
Anthony C. Hooper 68
Ranjeev Krishana 49
Thomas Malley 54
Alessandro Riva 62
Corazon (Corsee) D. Sanders 66
51
55 2010 10
2005 2009 BioDuro, LLC Pharmaceutical Product
Development Inc. 2002 2004 Galenea Corp.
1998 2002 Telephia, Inc. 2007 (The Nielsen
Company) 1997 1998 Genta Inc.
(McKinsey & Company)
1990 6 1996 1
185 2022
60 2016 2 2011
2003 2010
2020 1997 2010
Howard Hughes Medical Institute 2001 2010
George L. MacGregor 2004 Joyant
Pharmaceuticals, Inc.
2197 1984 7
1991 5
2004 2013
2022 186
Margaret Han Dugan 66 2022 2 1 Dugan Dracen
2018 Dracen 20
Dugan American
Cyanamid Dugan
Dugan
Donald W. Glazer 78 2013 2 2000 Glazer GMO
Trust 2005 GMO Trust Glazer Provant,
Inc. 2002 2010 1992
1995 Glazer Mugar/Glazer Holdings 1992 1993
WHDH-TV, Inc. 1997 Glazer Goodwin Procter LLP
1970 1978 Ropes & Gray LLP 1978 1992
Ropes & Gray 1978 1991
Provant, Inc. Glazer Environics Inc.
Kronos Incorporated Reflective Technologies, Inc. Teleco Oilfield Services Inc.
Glazer 1966 6 1969 6
1970 5
Glazer Glazer and FitzGibbon on Legal Opinions
Massachusetts Corporation Law& Practice Glazer
Michael Goller 48 2015 4 Goller Baker Brothers Investments
2005 Baker Brothers Goller 1999 2003 JPMorgan Partners,
LLC 1997 1999 Goller (Merrill
Lynch and Co.) Goller DBV Technologies SA
2017 2019 Levo Therapeutics, Inc. Goller 1997
5 2005 5
Goller
187 2022
Anthony C. Hooper 68 2020 1 Hooper 2020 1
2018 9 2020 1 2011 2018 8
2010 2011 Hooper Bristol Myers Squibb Company (BMS)
2009 2010 Hooper BMS 2004
2009 Hooper BMS Hooper BMS
BMS Hooper Hooper
1978 1988 MBA Hooper MannKind Corporation
MNKD Hooper Hooper
Ranjeev Krishana 49 2014 10 2020 2
Krishana 2011 Baker Bros. Advisors LP Baker Bros.
Krishana (Pfizer, Inc.)
Krishana 2003 2007 2008 2011
2008 2010 Krishana Krishana
Accenture plc Krishana 1995 5
2001 6 Krishana
Thomas Malley 54 2016 1 2007 5 Malley
Mossrock Capital, LLC 1991 4 2007 5 Malley Janus Mutual
Funds 1999 1 2007 5 Malley Janus Global Life
Sciences Fund Janus 1991 1998 Malley
Janus Malley 1991 6
Malley Kura Oncology, Inc.
2015 Kiniksa Pharmaceuticals, Ltd. 2016
OvaScience Inc. 2018 12 Millendo Therapeutics, Inc.
2012 2017 Synageva BioPharma Corp. 2015 5
2006 2015 Puma Biotechnology, Inc.
2011 2015 Cougar Biotechnology, Inc. 2009 7
2007 2009 Malley
2022 188
Corazon (Corsee) D. Sanders 66 2020 8 Sanders
(Bristol Myers Squibb Corporation) 2019 11
2020 2 Sanders 2018 3 2019 11
2017 1 2018 3 Juno Therapeutics
1994 2017
Sanders Genentech Genentech (Late Stage
Portfolio Committee) Genentech (Late Stage Clinical Operations)
Genentech Genentech Genentech DATA
Sanders (Fred Hutchinson Cancer
Research Center) (Board of Trustees)
Molecular Templates Inc. MTEM Legend Biotech Corporation LEGN
AltruBio Inc. AbGenomics Ultragenyx Pharmaceutical Inc.
RARE Sanders (Magna Cum Laude)
Sanders
Alessandro Riva 62 2022 2 1 Riva Intima Bioscience,
Inc. 2019 2021
Ichnos Sciences
2017 2019 Riva
Kite Pharma
2005 2016 Riva
GSK Riva
Century Therapeutics, Inc.
iPSC NK T Riva Transgene SA TNG TNG
Farmitalia Carlo Erba Rhne-Poulenc Rorer Aventis
(BCIRG) (CIRG) Riva
Riva
189 2022
51 2014 10 (Hillhouse Capital)
2005
1995 7 2003 5
2023 4 18
61
52
46
* 2022 3 2 2022 4 3
61 2018 4 2021 4 1
25 17
2018 4 2009 2018 4
2017 2018 4 (Pfizer Essential Health)
2004 2009 2001 2004
1992
2008 2018 (RDPAC) 2015 2018
(NDPE)
2017 2017
2017 1993 4 1990 1
2022 190
52 2021 6 2020 6
2018 2020 (Alexion
Pharmaceuticals) 50
2015 2018 (Quest Diagnostics)
2007 2012 Johnson & Johnson
(J&J) (Xian-
Janssen) (PepsiCo) 1999 (Duke
University) (Fuqua School of Business) 1992
46 2021 4 2011 5
20 10
Joyant Pharmaceuticals 1996
2001
191 2022
13.51B(1)
2022 12 31
13.51B(1)
2022 1 31
Margaret Han Dugan 2022 2 1
2022 2 25
2022 9 13
Alessandro Riva 2022 2 1
2022 11 20
2022 6 22
Corazon (Corsee) D. Sanders 2022 11 20
Anthony C. Hooper Anthony C. Hooper 2023 4
17
2022 192
2022 12 31
2010 10 28 2018
8 8 06160 2016 2 3
BGNE 2021 12 15
688235
EUSA Pharma
ociperlimab
4 17
195 198 2023 4 25
2022 12 31
193 2022
1
151
2022 12 31 293
2022 12 31 69.0%
18.1% 2022 2021 12 31
2021 12 31
73.6% 26.0%
2022 2021 12 31 23.9% 29.4%
2022 2021 12 31 12.0% 16.2%
2022 12 31 5%
2022 194
2023 4 25
2022 12 31
Anthony C. Hooper 2023 4 17
2023 4 18
195 2022
2022 196
197 2022
10-K
2020 1 2
174.85 15,895,001 206,635,013
20.5% 2,779,241,000 (a) 2019
10 30 30 36% (b)
1.00 7.84 2019 10 31
26% (c) 2019 10 31 26%
2022 198
2019 11 29
2022 12 31
2022
2021 2022 12 31
12 31 12 31
(%)
(a)
2,779,241 100.00% 1,869,643 2,080,068 699,173
(a) 12.5
2019 11 29
2026
2019 11 1 2019 12 9 2020 1 3
2020 9 24
20.6%
20.4%
75,000,000
199 2022
90
2020 12 1 (a)
20% (b) 60 (c)
2020 3 18 2020 9 25 2020 10
9
2021 9 165,529
2,151,877 50,000,000 2022 12 31
50,000,000
2020 7
2020 7 15 2020
202,995,338 2020 7 12
14.2308 185 145,838,979
20.8
(a)
(b)
(c)
(d)
2020 7 13 2020 7 16
2022 12 31
2022 200
2021 12 15 2021 6 16
2021
192.60
234.89 391.68 115,055,260
3,392,616,000
(i) (ii)
(iii) (iv) (v)
2020 11 16 2021 1 29 2021 4 20 2021 5
14 2021 6 1 2021 6 21 2021 6 28 2021 6 30 2021 7 9 2021
7 28 2021 10 15 2021 11 16 2021 11 23 2021 11 24 2021 11 29
2021 11 30 2021 12 2 2021 12 6 2021 12 7 2021 12 13 2021
12 21 2021 12 28 2022 4 29 2022 6 27 2022 8 30 2022 9 28
2021 4 30
201 2022
2022 12 31 83 134
2022 12 31
2022
2021 2022 12 31
12 31 12 31
13,245,940 – 4,499,849 8,746,091
467,700 – 376,601 91,099
150,000 – 153,451 – 3,451*
136,360 – 71,580 64,780
6,000,000 – 2,662,674 3,337,326
1,630,155 – 489,000 1,141,155
21,630,155 – 8,253,155 13,377,000
*
2022 202
2022 12 31
2022 12 31 296
31 31
2022 12 31 11
2022 12 31 538.1 2021 629.7
203 2022
2022 12 31 6.8 2021 0.7
2022 12 31
2020 3 17
2020 9 24
20.6% 2021 9
165,529 2,151,877 50
2022 12 31
2022 204
2022 12 31
Margaret Han Dugan 1
Donald W. Glazer
Michael Goller
Anthony C. Hooper 2
Ranjeev Krishana
Thomas Malley
Alessandro Riva 1
Corazon (Corsee) D. Sanders
(1) 2022 2 1 Margaret Han Dugan Alessandro Riva
(2) Anthony C. Hooper 2023 4 17 2022 12 31
2023 4 16 Anthony C. Hooper
* 2022 1 31
2022 6 22
205 2022
2023
2024 2025
2023 Margaret Han Dugan
Alessandro Riva Margaret Han Dugan Alessandro Riva 2022 2
Margaret Han Dugan Alessandro Riva 2022
2023 Margaret Han
Dugan Alessandro Riva 2026
2022 12 31 3.13
Anthony C. Hooper
2022 206
2023 3 27
65,000 2022 5,000
2023 4 1 2022
65,000(1)
35,000(2)
17,500(1)
30,000(2)
15,000(1)
18,000(3)
9,000(4)
20,000(5)
10,000(6)
20,000(5)
10,000(6)
(1) 2022 5,000
(2) 2022 10,000
(3) 2022 3,000
(4) 2022 1,500
(5) 2022 2,000
(6) 2022 1,000
207 2022
400,000
400,000 2021
50% 50%
(i) 100% (ii)
100%
(i) (ii)
2016
2016
1,000,000
2019 2
2021 2022 12 31
21.2 20.6
26 27 28
2022 208
2017 4 25
800,000
100%
60
(i) (ii) (iii)
(iv)
(i) (ii) 12 (iii)
(iv) 20,000 (v)
2015 2017 20
20 12
24
18
209 2022
2010
2018 7 24 2018
2021 2 24 2021 1 1 2023 12 31
2021 2018
100,000
2021 2021 1 1 2023 12 31
30 2021
2023
28
2022 12 31
2022 12 31
2022 210
2022 12 31
2022 12 31
18
2022 12 31
8.10
211 2022
2022 12 31 XV
(a) XV 7 8
(b)
352 (c)
(1)
25,204,014(2) 1.86%
9,633,361(3) 0.71%
102,188 (4)
0.008%
7,727,927(5) 0.57%
29,072,476 (6)
2.15%
510,941 (7)
0.04%
481,533(8) 0.04%
1,456,052 (9)
0.11%
15,797,527 (10)
1.17%
172,372(11) 0.01%
4,123,998 (12)
0.31%
1,127,542(13) 0.08%
50 (14)
0.000004%
Margaret Han Dugan 73,918 (15)
0.005%
Donald W. Glazer 3,150,782(16) 0.23%
Michael Goller 413,335 (17)
0.03%
Anthony C. Hooper 143,988 (18)
0.01%
Ranjeev Krishana 413,335(19) 0.03%
Thomas Malley 1,326,083 (20)
0.10%
Alessandro Riva 73,918(21) 0.005%
Corazon (Corsee) D. Sanders 104,117(22) 0.008%
396,253 (23)
0.03%
2022 212
(1) 2022 12 31 1,351,430,376
(2) (1) 1,260,566 (2) 23,499,740
(3) 443,708
(3) Roth IRA PENSCO
(4) The John Oyler Legacy Trust
(5)
(6) Oyler Investment LLC
Oyler Investment LLC 99%
(7) The Oyler Family Legacy Trust
(8)
(9)
(10) (1) 5,464,801 (2) 10,219,971
(3) 112,755
(11)
(12) Wang Investment LLC Wang Investment LLC 99%
213 2022
(13)
(14)
(15) (1) Dugan Dugan 57,226
(2) Dugan 16,692
(16) (1) Glazer 2,746,729 (2) Glazer Glazer
379,561 (3) Glazer 24,492
(17) (1) Goller 17,082 (2) Goller Goller
379,561 (3) Goller 16,692
(18) (1) Hooper Hooper 119,496
(2) Hooper 24,492
(19) (1) Krishana 17,082 (2) Krishana Krishana
379,561 (3) Krishana 16,692
(20) (1) Malley 407,082 (2) Malley Malley
902,309 (3) Malley 16,692
(21) (1) Riva Riva 57,226
(2) Riva 16,692
(22) (1) Sanders 7,800 (2) Sanders Sanders
79,625 (3) Sanders 16,692
(23) (1) 379,561
(2) 16,692
2022 12 31
(a) XV 7
8
(b) 352 (c)
2022 214
2022 12 31
XV 2 3
336
(1)
Amgen Inc. 246,269,426 18.22%
Julian C. Baker (2)
152,875,363 11.31%
Felix J. Baker(2) 152,875,363 11.31%
Baker Bros. Advisors (GP) LLC(2) 152,419,703 11.28%
Baker Bros. Advisors LP (2)
152,419,703 11.28%
Baker Brothers Life Sciences 139,823,423 10.35%
Capital, L.P.(2)
HHLR Fund, L.P.(3) 129,433,059 9.58%
HHLR Advisors, Ltd. (3)
133,587,655 9.88%
The Capital Group Companies, 108,706,886 8.04%
Inc. (4)
JPMorgan Chase & Co.(5) 13,269,714 0.98%
13,208,484(S) 0.98%(S)
1,192,989 0.09%
1,210,887 0.09%
6,565 0.0005%
84,543,618 6.26%
(S)
(1) 2022 12 31 1,351,430,376
(2) Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC Baker Bros. Advisors (GP) LLC
Baker Bros. Advisors LP BBA BBA 667, L.P. Baker Brothers Life Sciences, L.P.
Baker Brothers Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P.
BBA Michael Goller Ranjeev Krishana
BBA
215 2022
Baker Brothers Life Sciences Capital, L.P. 2021 12 15 2021 12 15
140,543,649 Baker Brothers Life Sciences, L.P.
Julian C. Baker Felix J. Baker Baker Bros. Advisors (GP) LLC BBA 667, L.P.
11,152,058 Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA Baker Brothers
Life Sciences Capital, L.P. Baker Brothers Life Sciences, L.P. 140,543,649 723,996
BBA
Julian C. Baker Felix J. Baker 270,868 FBB3 LLC
151,004
(3) (i) 133,587,655 HHLR Fund, L.P. YHG Investment, L.P. (ii) 13,447,603 Hillhouse
BGN Holdings Limited HHLR Adrisors, Ltd. YHG Investment, L.P. HHLR Fund,
L.P. Hillhouse Capital Management, Ltd. Hillhouse Fund II, L.P.
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited HHLR Adrisors, Ltd.
HHLR Fund, L.P. YHG Investment, L.P. 133,587,655 Hillhouse Capital
Management, Ltd. Hillhouse BGN Holdings Limited 13,447,603
Hillhouse Fund II, L.P. Hillhouse BGN Holdings Limited 13,447,603
(4) (i) 14,715,171 Capital International, Inc. (ii) 715,234 Capital International Limited
(iii) 2,129,219 Capital International Sarl (iv) 87,554,010 Capital Research and
Management Company (v) 198,926 Capital Group Investment Management Private Limited
(vi) 3,394,326 Capital Group Private Client Services, Inc.
Capital Group International, Inc. Capital Research and Management Company Capital
International, Inc. Capital International Limited Capital International Sarl Capital Group Investment
Management Private Limited Capital Group Private Client Services, Inc. Capital Group International,
Inc. Capital Research and Management Company Capital Group
International, Inc. Capital International, Inc. Capital International Limited Capital International
Sarl Capital Group Investment Management Private Limited Capital Group Private Client Services, Inc.
21,152,876
Capital Research and Management Company The Capital Group Companies Inc.
The Capital Group Companies Inc. Capital Research and Management Company
103,965,748
(5) JPMorgan Chase & Co. 2022 12 29
JPMorgan Chase & Co. 100,505,091 13,517,314
84,540,483 1,430,466 646,946
2022 12 31
XV 2 3
336
2022 216
2011 2016 2018 2018
2022 6 22 2016 2018
2023 1 1 2023 1
1
49,490,753
3.69% 2022 9 1 2023 3 31
2018 2023 3 31
1. 2011
2011 4 15 2015 4 17 2011 2016 2
2 2016 2011
2011
2011 43,560,432 2016 2 2 2016
2011
2022 1 1 2011 2,908,297 2011 2022 1 1
2022 12 31 265,109 2022 12 31 2023 4 18
2,643,042 1,688,704 2023 4 18
0.12% 2011
217 2022
2011 2011
10
2011
2011
0.01 1.85
2011
2011 2016 2 2 2016
2011
2011 2018 7 30
2022 218
2011
2022 12 31 2011 240 2011
2011 5 20 2016 1 31 2022 1 1
2022 12 31 2011
2022 2022
1 1 12 31
2011 5 20 (1)
10 0.01 – – – – –
2013 4 3 (1)
10 0.01 879,267 – – – 879,267
2015 6 29 (1)
10 0.50 500,000 – – – 500,000
Thomas Malley 2016 1 25 (2)
10 1.85 552,752 – – – 552,752
2012 7 6 (3)
10 0.01 12 – – – 12 –
2013 4 3 (3)
10 0.01 12 – – – 12
2015 6 29 (3)
10 0.50 11 – – – 11
2011 5 20 10 0.01 828,937 – 165,113(4) – 130 663,694
2016 1 31 1.85
(3)
2011 5 20 10 0.01 147,306 – 99,996(5) – 4 47,306
2016 1 31 1.85
(3)
2,908,297 – 265,109 – 146 2,643,042
(1) 20% 80% 20% 48
219 2022
(2)
(3) 20%/25% 80%/75% 20%/25% 48/36
(4) 13 10.37 20.74
(5) 13 10.08 12.43
2. 2016
2018 11 7 2018 12 7 2016 2016 1
14 2016
2016 2020 4 13 2020 6 17
2016 2016
57,200,000 2016 2030 2022 4 17 2022 6
22 2016
2016 2016 2016 66,300,000
2016 20
2016
2016
2022 220
2016 2022 6 22
10% 2016
30%
2022 1 1 2016 50,871,196 2022 1 1 2022 12 31
51,224,485 2016 2022
12 31 2023 4 18 75,034,504 74,808,629 2016
2022 1 1 2016 140,532,001 2016 2022
1 1 2022 12 31 17,714,112 2022 12 31 2023 4
18 189,114,821 184,187,444 2023 4 18
13.56% 2016
2016
12
1%
221 2022
10
(i)
1/13 (ii)
1/13
2016
2016
2016 2030 4 13 2016 7
2016
2022 12 31 2016 1,078
2016 2016 2 8 2022 12 31
2016 0.5 28.81
2022 222
2022 1 1 54,065,073 2016 2022
12 31 58,683,144 2016
2022 2022
1 1 12 31
(1) (2)
2016 10 2.79 2.84 2,047,500 – – – – 2,047,500
11 16 (3)
2017 10 6.73 7.70 935,000 – – – – 935,000
9 27 (3)
2018 10 13.37 13.04 996,810 – – – – 996,810
4 30 (3)
2018 10 12.70 12.34 1,310,088 – – – – 1,310,088
6 26 (3)
2019 10 9.25 9.23 2,193,282 – – – – 2,193,282
6 5 (3)
2020 10 13.33 13.42 1,821,976 – – – – 1,821,976
6 17 (3)
2021 10 25.54 26.53 906,906 – – – 906,906
6 16 (3)
2022 10 11.74 11.98 – 1,887,678 – – – 1,887,678
6 22 (3)
2016 10 2.79 2.84 1,613,430 – – – – 1,613,430
11 16 (3)
2017 9 10 6.73 7.70 750,000 – – – – 750,000
27 (3)
2018 10 12.70 12.34 655,044 – – – – 655,044
6 26 (3)
2019 10 9.25 9.23 747,708 – – – – 747,708
6 5 (3)
223 2022
2022 2022
1 1 12 31
(1) (2)
2020 10 13.33 13.42 560,599 – – – – 560,599
6 17 (3)
2021 10 25.54 26.53 241,839 – – – – 241,839
6 16 (3)
2022 10 11.74 11.98 – 471,913 – – – 471,913
6 22 (3)
Anthony C. Hooper* 2020 10 12.62 12.22 21,970 – – – – 21,970
3 3 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 26.53 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
2016 10 2.61 15.49 2.42 188,926 – 188,916 – 10
2 8 (4)
2017 10 2.94 13.93 3.15 65,988 – 65,988 – –
6 2 (5)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
Margaret Han Dugan 2022 10 16.47 16.22 – 22,581 – – – 22,581
2 28 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
2022 224
2022 2022
1 1 12 31
(1) (2)
Donald W. Glazer 2017 10 2.84 2.83 199,992 – – – – 199,992
4 19 (4)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
Michael Goller 2017 10 2.84 2.83 199,992 – – – – 199,992
4 19 (4)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
Ranjeev Krishana 2017 10 2.84 2.83 199,992 – – – – 199,992
4 19 (4)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
225 2022
2022 2022
1 1 12 31
(1) (2)
Thomas Malley 2017 10 2.94 3.15 169,988 – – – – 169,988
6 2 (5)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
Corazon D. 2020 10 18.50 18.26 27,482 – – – – 27,482
Sanders 8 24 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
Alessandro 2022 10 16.47 16.22 – 22,581 – – – 22,581
Riva 2 28 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
2018 10 12.92 13.85 12.72 63,290 – 63,284 6 –
4 1 (4)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – 17,498 – –
6 16 (5)
2022 226
2022 2022
1 1 12 31
(1) (2)
2017 10 2.84 2.83 199,992 – – – – 199,992
4 19 (4)
2018 10 15.73 16.15 17,442 – – – – 17,442
6 6 (5)
2019 10 9.25 9.23 64,610 – – – – 64,610
6 5 (5)
2020 10 13.33 13.42 45,383 – – – – 45,383
6 17 (5)
2021 10 25.54 25.63 17,498 – – – – 17,498
6 16 (5)
2022 10 11.74 11.98 – 34,645 – – – 34,645
6 22 (5)
2018 10 13.37 13.04 766,599 – – – – 766,599
4 30 (6)
2019 10 9.25 9.23 797,550 – – – – 797,550
6 5 (3)
2020 10 13.42 13.33 756,821 – – – – 756,821
6 17 (3)
2021 10 25.54 25.63 483,678 – – – – 483,678
6 16 (3)
2022 10 11.74 11.98 – 1,061,814 – – – 1,061,814
6 22 (3)
2020 10 14.55 14.66 104,754 – – – – 104,754
6 30 (3)
2021 10 25.54 26.53 177,853 – – – – 177,853
6 16 (3)
2022 10 11.74 11.98 – 589,888 – – – 589,888
6 22 (3)
227 2022
2022 2022
1 1 12 31
(1) (2)
2016 10 2.27 10.66 2.29 233,948 – 233,948 – – –
7 13 (3)
2017 10 3.50 10.66 3.49 999,999 – 999,999 – – –
6 27 (3)
2018 10 12.70 12.34 364,208 – – – – 364,208
6 26 (3)
2019 10 9.25 9.23 558,285 – – – – 558,285
6 5 (3)
2020 10 13.33 13.42 525,564 – – – – 525,564
6 17 (3)
2021 10 25.54 26.53 332,527 – – – – 332,527
6 16 (3)
2022 10 11.74 11.98 – 707,876 – – – 707,876
6 22 (3)
2016 10 2.26 2.27 207,575 – – – – 207,575
9 2 (3)
2017 10 3.50 3.49 850,465 – – – – 850,465
6 27 (3)
2018 10 12.70 15.31 12.34 122,798 – 78,000 – – 44,798
6 26 (3)
2019 10 9.25 9.23 211,276 – – 115,752 – 95,524
6 5 (3)
2020 10 13.33 16.85 13.42 204,971 – 68,172 136,799 – –
6 17 (3)
2021 10 25.54 26.53 157,196 – – 117,897 – 39,299
6 16 (3)
2022 228
2022 2022
1 1 12 31
(1) (2)
2016 7 13 (3) 10 2.27 2.29 15,385 – – – 15,385
2016 7 13 (3) 10 2.27 12.29 2.29 3,247,450 – 16,029 – 1 3,231,420
2016 7 22 (3) 10 2.13 13.97 2.10 105,487 – 14,001 – 26 91,460
2016 7 22 (6) 10 2.13 14.94 2.10 981,325 – 194,025 – 692 786,608
2016 7 29 (3) 10 2.11 2.02 26 – – – 12 14
2016 8 9 (3) 10 2.04 2.10 – – – – –
2016 8 22 (3) 10 2.28 2.24 – – – – –
2016 9 12 (3) 10 2.33 2.42 – – – – –
2016 9 19 (3) 10 2.51 2.38 – – – – –
2016 9 26 (3) 10 2.35 2.27 – – – – –
2016 10 12 (3) 10 2.48 12.06 2.42 134,498 – 134,492 – 6
2016 10 12 (6) 10 2.48 12.02 2.42 1,020 – 1,020 – –
2016 10 17 (3) 10 2.42 2.55 61,399 – – – 61,399
2016 11 1 (3) 10 2.56 2.57 – – – – –
229 2022
2022 2022
1 1 12 31
(1) (2)
2016 11 7 (3)
10 2.43 2.46 – – – – –
2016 11 8 (3)
10 2.46 2.51 – – – – –
2016 11 16 (3)
10 2.79 2.84 – – – – –
2016 11 21 (3)
10 2.46 2.42 – – – – –
2016 11 28 (3)
10 2.49 17.48 2.38 39,000 – 39,000 – –
2016 11 30 (3)
10 2.43 2.44 1,274 – – – 1,274
2016 12 1 (3)
10 2.44 2.37 – – – – –
2016 12 9 (3)
10 2.07 2.09 34,099 – – – 34,099
2017 1 3 (3)
10 2.34 12.63 2.39 16,965 – 9,165 – 7,800
2017 1 5 (3)
10 2.44 2.39 63,661 – – – 63,661
2017 1 9 (3)
10 2.37 16.24 2.43 158,496 – 26,000 – 132,496
2017 1 17 (3)
10 2.51 2.53 – – – – –
2017 1 17 (6)
10 2.51 15.06 2.53 88,556 – 41,340 – 47,216
2017 1 23 (3)
10 2.46 14.33 2.49 108,875 – 108,875 – –
2017 1 30 (3)
10 2.80 2.62 – – – – –
2022 230
2022 2022
1 1 12 31
(1) (2)
2017 2 1 (3)
10 2.68 2.77 144,989 – – – 144,989
2017 2 6 (3)
10 2.76 2.76 32,201 – – – 32,201
2017 2 8 (3)
10 2.67 2.78 – – – – –
2017 2 13 (3)
10 2.77 13.82 2.77 71,643 – 31,200 – 40,443
2017 2 27 (3)
10 2.97 2.93 – – – – –
2017 3 6 (3)
10 3.14 3.06 – – – – –
2017 3 13 (3)
10 3.08 15.19 3.02 142,701 – 26,000 – 116,701
2017 3 20 (3)
10 3.04 3.04 84,968 – – – 84,968
2017 3 27 (3)
10 2.79 2.79 – – – – –
2017 3 31 (6)
10 2.81 15.60 2.82 85,683 – 44,278 – 41,405
2017 4 3 (3)
10 2.82 13.99 2.82 5,928 – 5,928 – –
2017 4 10 (3)
10 2.86 2.91 – – – – –
2017 4 11 (3)
10 2.91 2.95 – – – – –
2017 4 17 (3)
10 2.92 13.91 2.95 109,590 – 98,163 – 11,427
2017 4 24 (3)
10 2.82 2.89 – – – – –
231 2022
2022 2022
1 1 12 31
(1) (2)
2017 4 26 (3)
10 3.01 3.09 – – – – –
2017 5 1 (3)
10 3.14 15.86 3.13 531,245 – 270,582 – 260,663
2017 5 2 (6)
10 3.13 13.94 3.12 115,349 – 10,244 416 104,689
2017 5 3 (3(3)
10 3.12 3.12 11,999 – – – 11,999
2017 5 8 (3)
10 3.02 2.98 – – – – –
2017 5 10 (3)
10 2.88 2.92 – – – – –
2017 5 15 (3)
10 2.81 2.90 9,100 – – – 9,100
2017 5 30 (3)
10 2.88 2.88 21,060 – – – 21,060
2017 6 1 (6)
10 2.83 14.68 2.94 1,150,045 – 55,848 507 1,093,690
2017 6 12 (3)
10 2.99 10.69 3.00 12,844 – 117 – 12,727
2017 6 14 (3)
10 3.04 14.12 3.05 776,581 – 192,686 – 583,895
2017 6 15 (6)
10 3.05 14.64 3.04 4,029,896 – 872,989 10,088 2,535 3,144,284
2017 6 21 (3)
10 3.31 3.45 17,784 – – – 17,784
2017 6 23 (3)
10 3.41 3.45 – – – – –
2017 6 27 (3)
10 3.50 11.75 3.49 2,233,309 – 49,296 – 2,184,013
2022 232
2022 2022
1 1 12 31
(1) (2)
2017 6 29 (3)
10 3.50 3.45 43,654 – – – 43,654
2017 7 10 (3)
10 5.40 13.76 5.45 156,624 – 149,864 – 6,760
2017 7 17 (3)
10 5.67 14.19 4.19 41,106 – 41,106 – –
2017 7 17 (6)
10 5.67 15.39 4.19 366,366 – 73,541 – 292,825
2017 7 24 (3)
10 5.95 5.65 – – – – –
2017 7 31 (3)
10 5.58 15.50 5.42 119,574 – 14,911 4,667 99,996
2017 7 31 (6)
10 5.58 13.75 5.42 371,072 – 34,801 – 336,271
2017 8 1 (3)
10 5.42 13.75 5.58 473,200 – 317,200 – 156,000
2017 8 2 (6)
10 5.58 5.45 – – – – –
2017 8 3 (3)
10 5.45 5.51 19,994 – – – 19,994
2017 8 7 (3)
10 5.56 16.15 5.95 114,309 – 16,809 – 97,500
2017 8 8 (3)
10 5.95 6.03 12,649 – – – 12,649
2017 8 10 (3)
10 5.95 5.59 – – – – –
2017 8 11 (3)
10 5.59 5.46 – – – – –
2017 8 17 (3)
10 5.39 12.09 5.32 18,317 – 18,317 – –
233 2022
2022 2022
1 1 12 31
(1) (2)
2017 8 25 (3) 10 5.38 5.29 – – – – –
2017 8 28 (3) 10 5.29 5.28 24,167 – – – 24,167
2017 8 31 (3) 10 5.30 5.30 – – – – –
2017 8 31 (6) 10 5.30 14.79 5.30 281,242 – 96,096 4,550 180,596
2017 9 5 (3) 10 5.78 5.68 269,997 – – – 269,997
2017 9 12 (3) 10 5.39 5.43 – – – – –
2017 9 13 (3) 10 5.43 5.82 – – – – –
2017 9 18 (3) 10 6.22 6.37 22,269 – – – 22,269
2017 9 22 (3) 10 6.53 16.62 6.55 90,155 – 21,567 – 68,588
2017 9 25 (3) 10 6.55 11.72 6.56 153,569 – 31,577 – 121,992
2017 9 26 (3) 10 6.56 8.71 – – – – –
2017 9 29 (3) 10 7.49 7.96 37,492 – – – 37,492
2017 11 1 (3) 10 7.10 6.84 226,356 – – – 226,356
2017 11 30 (3) 10 6.38 6.15 10,764 – – – 10,764
2018 1 5 (3) 10 7.72 7.58 19,071 – – – 19,071
2022 234
2022 2022
1 1 12 31
(1) (2)
2018 1 31 (3) 10 9.52 13.34 10.44 84,385 – 4,368 – 80,017
2018 2 28 (3) 10 11.61 11.04 7,904 – – – 7,904
2018 4 30 (3) 10 13.37 13.04 17,407 – – 2,990 8,268 6,149
2018 6 26 (3) 10 12.70 15.15 12.34 935,961 – 74,932 1,794 13,091 844,571
2018 6 29 (3) 10 11.90 11.83 12,103 – – – 12,103
2018 8 31 (3) 10 13.67 13.66 13,741 – – – 13,741
2018 8 31 (7) 10 13.67 13.66 108,537 – – – 108,537
2018 9 28 (3) 10 13.28 13.25 65,433 – – – 65,433
2018 9 28 (8) 10 13.28 13.25 39,260 – – – 39,260
2018 11 30 (3) 10 11.07 11.79 11,028 – – – 11,028
2018 12 31 (3) 10 10.53 16.23 10.79 144,053 – 6,682 4,108 133,263
2018 12 31 (8) 10 10.53 10.79 12,727 – – – 12,727
2019 1 25 (3) 10 9.62 10.44 38,649 – – – 38,649
2019 2 28 (3) 10 10.77 15.13 10.54 130,754 – 107,718 7,436 15,600
2019 3 5 (3) 10 11.68 11.51 78,494 – – – 78,494
235 2022
2022 2022
1 1 12 31
(1) (2)
2019 5 10 (3) 10 9.33 10.32 44,213 – – – 44,213
2019 6 5 (3) 10 9.25 14.31 9.23 3,074,162 – 524,186 249,249 1,651 2,299,076
2019 6 28 (3) 10 9.67 9.53 38,714 – – 24,609 14,105
2019 8 30 (3) 10 11.14 11.06 97,201 – – – 97,201
2019 11 29 (3) 10 15.71 15.83 39,221 – – 14,105 25,116 –
2019 12 31 (3) 10 12.80 12.92 29,523 – – 13,689 15,834
2020 3 3 (3) 10 12.62 15.08 12.19 20,657 – 7,800 12,857 –
2020 3 31 (3) 10 9.65 9.67 294,775 – – – 294,775
2020 5 12 (3) 10 12.56 15.19 12.18 38,597 – 23,920 14,677 –
2020 5 29 (3) 10 12.49 13.08 12.73 21,281 – 11,505 9,776 –
2020 6 17 (3) 10 13.33 15.26 13.42 2,220,140 – 92,690 484,666 99,541 1,543,243
2020 6 30 (3) 10 14.55 14.66 212,771 – – – 212,771
2020 8 7 (3) 10 17.24 16.99 40,248 – – – 40,248
2020 8 31 (3) 10 18.69 18.85 14,040 – – 8,528 5,512 –
2020 9 30 (3) 10 21.65 22.03 8,021 – – – 8,021
2022 236
2022 2022
1 1 12 31
(1) (2)
2020 11 6 (3) 10 23.08 23.07 175,708 – – – 175,708
2020 11 30 (3) 10 21.99 20.99 26,962 – – 5,915 5,291 15,756
2021 1 22 (3) 10 27.46 28.81 64,441 – – 6,890 2,288 55,263
2021 2 26 (3) 10 25.36 25.81 6,331 – – – 6,331
2021 3 31 (3) 10 25.61 26.78 158,834 – – 7,514 2,496 148,824
2021 5 7 (3) 10 24.15 24.78 84,240 – – – 84,240
2021 5 28 (3) 10 27.00 27.58 121,485 – – – 121,485
2021 6 16 (3) 10 25.54 26.53 2,333,955 – – 408,096 86,437 1,839,396
2021 6 30 (3) 10 27.48 27.28 88,829 – – 29,432 59,397
2021 8 6 (3) 10 25.84 25.61 158,262 – – 7,839 150,423
2021 8 31 (3) 10 23.22 23.72 153,322 – – – 153,322
2021 9 30 (3) 10 27.81 28.73 61,230 – – 4,212 57,018
2021 11 5 (3) 10 28.38 28.08 45,786 – – – 45,786
2021 11 30 (3) 10 26.40 26.85 64,649 – – – 64,649
2021 12 31 (3) 10 21.03 20.84 59,332 – – – 59,332
237 2022
2022 2022
1 1 12 31
(1) (2)
2022 1 27 (3) 10 17.27 18.61 – 371,059 – – 371,059
2022 2 28 (3) 10 16.47 16.22 – 171,626 – – 171,626
2022 3 31 (3) 10 15.85 15.46 – 135,694 – – 135,694
2022 5 6 (3) 10 12.27 12.50 – 80,821 – – 80,821
2022 5 31 (3) 10 10.30 10.56 – 123,604 – – 123,604
2022 6 22 (3) 10 11.74 11.98 – 6,111,027 – 294,337 5,816,690
2022 6 22 (9) 10 11.74 11.98 – 11,804 – – 11,804
2022 6 30 (3) 10 12.48 12.81 – 77,974 – – 77,974
2022 8 5 (3) 10 14.70 14,96 – 188,929 – – 188,929
2022 8 31 (3) 10 12.73 13.32 – 22,009 – – 22,009
2022 9 30 (3) 10 10.48 10.58 – 66,690 – – 66,690
2022 11 10 (3) 10 13.56 14.52 – 54,106 – – 54,106
2022 11 30 (3) 10 13.84 14.74 – 17,745 – – 17,745
2022 12 30 (3) 10 17.22 17.26 – 7,592 – – 7,592
54,065,073 12,516,816 5,623,280 2,022,498 252,967 58,683,144
2022 238
* Anthony C. Hooper 2023 4 17
(1) 13
(2) 13
(3) 25%
75% 25% 36
(4)
(5)
(6) 20% 80% 20% 48
(7) 48
(8)
(9) 50% 50% 50% 12
239 2022
2016
(3)
1,887,678 2022 6 22 (1) 11.98 – 11.74 11,999,969
471,913 2022 6 22 (1) 11.98 – 11.74 2,999,951
Anthony Hooper 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Margaret Han Dugan 22,581 2022 2 28 (2) 16.22 – 16.47 149,037
Margaret Han Dugan 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Donald W. Glazer 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Michael Goller 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Ranjeev Krishana 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Thomas Malley 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Corazon D. Sanders 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
Alessandro Riva 22,581 2022 2 28 (2) 16.22 – 16.47 149,037
Alessandro Riva 34,645 2022 6 22 (2) 11.98 – 11.74 199,967
34,645 2022 6 22 (2) 11.98 – 11.74 199,967
1,061,814 2022 6 22 (1) 11.98 – 11.74 6,749,952
589,888 2022 6 22 (1) 11.98 – 11.74 3,749,918
707,876 2022 6 22 (1) 11.98 – 11.74 4,499,968
2022 1 27 10.56 10.30
7,440,680 2022 12 30 (1) 18.61 – 17.27 48,008,319
12,516,816 80,105,854
(1) 25%
75% 25% 36
2022 240
(2)
(3)
2016
2022 12 31 2016 13,150
2016 2017 9 26 2022 12 31
2022 1 1 35,546,446 2016 2022 12
31 2016 55,397,173
2022 2022 2022
1 1 12 31
(1)
2018 4 30 13.37 143,754 – 143,754 – – 12.19
2018 6 26 12.70 47,086 – 47,086 – – 12.02
2021 6 16 25.54 146,250 – 36,556 – 109,694 10.52
2022 6 22 11.74 – 334,009 – – 334,009 –
2018 6 26 12.70 23,543 – 23,543 – – 12.02
2021 6 16 25.54 39,000 – 9,750 – 29,250 10.52
2022 6 22 11.74 – 83,499 – – 83,499 –
Anthony C. Hooper 2021 6 16 25.54 7,800 – – – 7,800 –
2022 6 22 11.74 – 16,692 – – 16,692 –
2021 6 16 25.54 7,800 – 7,800 – – 10.52
Margaret Han Dugan 2022 6 22 11.74 – 16,692 – – 16,692 –
Donald W. Glazer 2021 6 16 25.54 7,800 – – – 7,800 –
2022 6 22 11.74 – 16,692 – – 16,692 –
241 2022
2022 2022 2022
1 1 12 31
(1)
Michael Goller 2021 6 16 25.54 7,800 – 7,800 – – 10.52
2022 6 22 11.74 – 16,692 – – 16,692 –
Ranjeev Krishana 2021 6 16 25.54 7,800 – 7,800 – – 10.52
2022 6 22 11.74 – 16,692 – – 16,692 –
Thomas Malley 2021 6 16 25.54 7,800 – 7,800 – – 10.52
2022 6 22 11.74 – 16,692 – – 16,692 –
Corazon D. Sanders 2021 6 16 25.54 7,800 – 7,800 – – 10.52
2022 6 22 11.74 – 16,692 – – 16,692 –
Alessandro Riva 2022 6 22 11.74 – 16,692 – – 16,692 –
2021 6 16 25.54 7,800 – – 7,800 – –
2021 6 16 25.54 7,800 – 7,800 – – 10.52
2022 6 22 11.74 – 16,692 – – 16,692
2022 242
2022 2022 2022
1 1 12 31
(1)
2018 4 30 13.37 459,979 – 229,970 – 230,009 12.19
2019 6 5 9.25 216,736 – 108,368 – 108,368 10.58
2020 6 17 13.33 100,620 – 33,527 – 67,093 10.29
2021 6 16 25.54 78,000 – 19,500 – 58,500 10.52
2022 6 22 11.74 – 187,876 – – 187,876 –
2020 6 30 14.55 41,405 – 13,793 – 27,612 12.48
2021 6 16 25.54 28,678 – 7,163 – 21,515 10.52
2022 2 28 16.47 – 61,750 – – 61,750 –
2022 6 22 11.74 – 104,377 – – 104,377 –
2018 6 26 12.70 13,104 – 13,104 – – 12.02
2019 6 5 9.25 37,947 – 18,954 – 18,993 10.68
2020 6 17 13.33 69,875 – 23,283 – 46,592 10.29
2021 6 16 25.54 53,625 – 13,403 – 40,222 10.52
2022 6 22 11.74 – 125,255 – – 125,255 –
243 2022
2022 2022 2022
1 1 12 31
(1)
2018 6 26 12.70 11,141 – 11,141 – – 12.02
2019 6 5 9.25 31,434 – 15,704 15,730 – 10.68
2020 6 17 13.33 36,335 – 12,103 24,232 – 10.29
2021 6 16 25.54 25,350 – 6,331 19,019 – 10.52
2018 1 31 18.55 33,848,542 – 11,219,715 4,422,860 18,205,967 (2)
2021 12 31
2022 1 1 12.46 – 37,617,853 2,938 2,276,469 35,338,446 (3)
2022 12 31
2019 2 4 12.01 23,842 – 15,158 – 8,684 (4)
2021 12 31
2022 1 1 17.70 – 42,822 19,188 – 23,634 (5)
2022 12 31
35,546,446 38,707,669 12,090,832 6,766,110 55,397,173
(1) 13
(2) 13 10.10 16.92
(3) 13 16.92
(4) 13 10.10 16.92
(5) 13 16.92
2022 244
(4)
334,009 2022 6 22 (1) – 11.74 3,999,886
83,499 2022 6 22 (1) – 11.74 999,933
Anthony C. Hooper 16,692 2022 6 22 (2) – 11.74 199,893
Margaret Han Dugan 16,692 2022 6 22 (2) – 11.74 199,893
Donald W. Glazer 16,692 2022 6 22 (2) – 11.74 199,893
Michael Goller 16,692 2022 6 22 (2) – 11.74 199,893
Renjeev Krishana 16,692 2022 6 22 (2) – 11.74 199,893
Thomas Malley 16,692 2022 6 22 (2) – 11.74 199,893
Corazon D. Sanders 16,692 2022 6 22 (2) – 11.74 199,893
Alessandro Riva 16,692 2022 6 22 (2) – 11.74 199,893
16,692 2022 6 22 (2) – 11.74 199,893
187,876 2022 6 22 (1) – 11.74 3,999,886
61,750 2022 2 28 (1) – 16.47 999,970
104,377 2022 6 22 (1) – 11.74 4,999,873
125,255 2022 6 22 (1) – 11.74 5,999,945
2022 1 31 10.48
37,617,853 2022 12 30 (1) – 16.38 458,791,912
2022 1 31 16.38
42,822 2022 12 30 (3) – 17.22 757,899
38,707,669 482,348,341
(1) 25%
(2)
(3)
(4)
245 2022
3. 2018
2018 11 7 2018 12 7 2018
2018 6 6 2018 2019 6 5 2018
2021 6 2018
2021 9 1
2018
2018 15%
2018 2018
2018 2018 5%
2018
1% 10% 25,000
2022 246
3 1 9 1
2018
85%
2018
2018
247 2022
2018 7,355,315
2022 1 1 2018 5,194,546 2022 1 1
2021 9 1
1,528,475 2018 2022 12 31
2023 4 18 3,666,071 2,735,219 2018
2022 12 31 2022 12 31 2022
9 1
2018 7,355,315 2022 1 1 2018
5,194,546 2021 9 1 2022 3 1
1,528,475 2018
2022 12 31 2023 4 18 3,666,071 2,735,219 2023
4 18 0.20% 2018
2018
2018 2018 12 7
2018 5.5
2018
2021 9 1 2022 3 1 2022 9 1 2,992 3,106 3,039
2018
2022 248
2018
2021 9 1
2022 3 1 2022 3 1
2021 9 1
(1) (2)
2021 9 1 6 13.76 10,623 6,800
13.76
494
2021 9 1 6 11.22 15,117 8,317
2022 3 1 13.76 11.22
741
6,800
13.76
494
2021 9 1 6 11.22 20,538,382 9,169,704
2022 3 1 13.76 13.76
666,172
9,659,016
11.22
860,574
9,667,337
1. 2021 9 1 2022 3 1 23.72 16.20 184.71
126.40 4,107,060 31,956,623
5,284,675 41,290,434 2021 9 1 2022 3 1
2018
249 2022
2. 2021 9 1 2022 3 1
2018
2022 2 28 2022 8 31 13.76 11.22 1,528,475
2022 2 28 2022 8 31 16.47 12.73
128.59 99.90 10,803,886
84,351,988 11,373,333 89,260,078
3. 2022 9 1 10,512,096
930,852
4. 2018
4. 2018
2018 6 6 2018 12,000,000
2018
2022 6 22 2016 2018
2018 20
2018
2022 250
5635(c)(4)
2018
2018 12,000,000 2022 1 1 2018
9,344,659 2022 12 31 2018
2018 2022 6 22
2022 12 31 2023 4 18
0 0 2023 4 18 0% 2018
2022 1 1 2018 9,881,715 2022 12 31
2018 452,582 2018 2022 6 22
2022 12 31 2018 2022 12 31 2023 4 18
0 0 2023 4 18 0% 2018
2018
2018
2022 6 22 2016 2018 2018
2018
12
1%
251 2022
10
(i)
1/13 (ii)
1/13
2018
2018
2022 2022
1 1 12 31
(1) (2)
2018 8 31 (3)
10 13.67 14.05 13.66 30,901 9,828 21,073
30,901 9,828 21,073
2022 252
(1) 13
(2) 13
(3) 25%
75% 25% 36
Thomas Malley Anthony C. Hooper Corazon (Corsee) D.
Sanders 2022 12 31 Thomas Malley Corazon (Corsee) D. Sanders
Anthony C. Hooper Thomas Malley
2022 12 31
253 2022
13.20 13.21 13.22
2023 4 18
2018 8 8 2022
2022 3 23
2021
2022 3 23
Ernst & Young LLP
2022 12 31
Ernst & Young LLP 2023
2023 4 18
2022 254
2022 12 31
2022
C.2.1
Ranjeev Krishana
255 2022
3.21 D.3.3 D.3.7
Thomas Malley Anthony
C. Hooper 2023 4 17 Corazon (Corsee) D. Sanders
Thomas Malley 3.10(2) 3.21
3.25 E.1.2
Margaret Han Dugan Ranjeev Krishana Margaret Han Dugan
2022 6 22
2022 9 13 Margaret Han Dugan
B3.1
Donald W. Glazer Michael Goller Anthony C. Hooper
2023 4 17 Alessandro Riva Donald W. Glazer
2022 256
2022 12 31
B.8
2022 1 1
257 2022
2022 12 31
*
Margaret Han Dugan
Donald W. Glazer
Michael Goller
Anthony C. Hooper
Ranjeev Krishana
Thomas Malley
Corazon (Corsee) D. Sanders
Alessandro Riva
* Anthony C. Hooper 2023 4 17 2022 12 31
2023 4 16 Anthony C. Hooper
2022 1 31
2022 6 22
2022 258
2022
3.13
2023 2024
2025
259 2022
2022 260
10-K
261 2022
Thomas Malley Anthony C. Hooper Corazon (Corsee) D.
Sanders Thomas Malley Anthony C. Hooper Corazon (Corsee) D. Sanders
Anthony C. Hooper 2023 4 17 2022 12
31 2023 4 16 Anthony C. Hooper Thomas Malley
3.10(2) 3.21 Anthony C. Hooper
Corazon (Corsee) D. Sanders 3.10(2) 3.21
2022 12 31 13
271
www.beigene.com HKEX investors 2022
2021 2022 2022
2022 262
Margaret Han Dugan Ranjeev Krishana Margaret Han
Dugan 2022 6 22
2022 9 13 Margaret Han Dugan
2022 12 31 26
25,000,001 105,000,000
263 2022
2022 12 31 271
www.beigene.com HKEX
investors 2022
Donald W. Glazer Michael Goller Anthony C. Hooper
Alessandro Riva Donald W. Glazer 2022 1 31
2022 2 1
Alessandro Riva
2022 264
2022 12 31
www.beigene.com HKEX investors
2022
2022
3.13
2022 12 31
271 Margaret
Han Dugan Michael Goller Thomas Malley Alessandro Riva Corazon (Corsee) D.
Sanders Alessandro Riva 2022
11 20 Alessandro Riva Corazon (Corsee) D. Sanders
www.beigene.com HKEX investors
265 2022
2022 12 31
271
Anthony C. Hooper Margaret Han Dugan Ranjeev Krishana Corazon (Corsee)
D. Sanders Anthony C. Hooper 2022 2 25
Margaret Han Dugan 2022 6 22
www.beigene.com HKEX investors
2022 266
2020
2022 www.beigene.com
HKEX investors
2023 4 18
11
2 9
1 3
6
1
LGBTQ+ 1
2022
2021 24%
2022 33% 52%
2023 4 25
267 2022
2021
2022 268
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana
Bay,Grand Cayman KY1-1108, Cayman Islands (a) (b)
1934 14a-8(b)(2)
(c)
(d) (e)
(f) (i) (ii)
(g)
269 2022
A.2.1
2022 12 31
2022 270
2022 12 31
*
7/7 1/1
Anthony C. Hooper (5)
7/7 13/13 4/4 1/1
7/7 4/4 1/1
(4)
2/7 3/5 2/4 0/1
Margaret Han Dugan (2)
7/7 1/5 4/4 3/4 1/1
Donald W. Glazer 7/7 1/1
Michael Goller 7/7 4/4 1/1
Ranjeev Krishana 7/7 5/5 4/4 1/1
Thomas Malley 7/7 11/13 4/4 1/1
Alessandro Riva (3)
7/7 4/4 1/1
Corazon (Corsee)
D. Sanders 7/7 13/13 4/4 4/4 1/1
(1)
6/7 5/5 3/4 1/1
* 2022 12 31
2022 12 31
(1) 2022 1 31
(2) 2022 2 1 Margaret Han Dugan
2022 2 25 Dugan 2022 9 13 Dugan
271 2022
(3) 2022 2 1 Alessandro Riva
2022 11 20 Alessandro Riva
(4) 2022 6 22
(5) Anthony C. Hooper 2023 4 17
C.2.7 2022 12 31
2022 12 31
2022 12 31
2022 272
2022 2 1 Margaret Han Dugan Alessandro Riva 2022 1
Dugan Riva
2022 12 31 Anthony C. Hooper Margaret Han Dugan
Donald W. Glazer Michael Goller Ranjeev Krishana Thomas Malley
Alessandro Riva Corazon (Corsee) D. Sanders
2022 2021 12 31 Ernst
& Young LLP
2022 2021
7,037 7,227
57 –
7,094 7,227
10-Q
2022
273 2022
2019 10 31 2020
1 2
18.2% 14A
14A
12.5
LUMAKRAS
(sotorasib)
2022 274
sotorasib (AMG 510)
AMG 510
2023 2 (i) 2023 1 1 2023 8
31 AMG 510 (ii) AMG 510
14A.52
14A.53(1)
14A.52 14A.53(1)
(a) 14A
(b)
(c)
(d)
14A.55 14A.56
(e) 2019 11 1
275 2022
(a)
= 50% x
(b)
(i) (ii) (iii) (x)
(y)
20 AMG
510
= x
= x
2022 276
12.5
1,250 3,750
(a) (b) (c)
14A.56
3000 740
2022 12 31
2022 12 31
(a)
(b)
(c)
277 2022
2020 3 17
2020 9 24
20.6%
20.4% (i)
(ii)
2020 12 1 (a)
20% (b) 60
(c)2023 12 1
2020 3 18 2020 9 25 2020 10
9
2021 9 165,529
2,151,877 50,000,000 2022
2022 278
2020 9 24
73,640,000 500,000,000 14,728,000 100,000,000
58,912,000 400,000,000
200,000,000 (i)2021 11
9 (ii) 2021 10 8
(i)2022 11 9
(ii) 2022 10 10
13,980,000 100,000,000
14A 16
2022 12 31 14A.71
2,069,546
399.43 137
15
10
2022 12 31 28
279 2022
14A
Committee of Sponsoring Organizations of the Treadway Commission
2013
404
2022 280
281 2022
(i) (ii)
2022 282
2022 12 31
D.2.3
Chan Lee
2022 12 31 3.29
61 62
21
21
21
283 2022
(Mourant
Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-
1108,Cayman Islands
(Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana
Bay, Grand Cayman KY1-1108, Cayman Islands [ ]
(i)
(ii) (iii)
(iv)
(v) (vi)
2023
2022
2022 284
290 396
2022 12 31
2022 12 31
285 2022
2022 12 31
1,640.5 2022 12 31
139.2
2
2022 286
287 2022
2022 288
2023 3 29
289 2022
12 31
2022 2021
3,869,564 4,375,678
5 196 328
6 665,251 2,241,962
7 173,168 483,113
8 282,346 242,626
14 216,553 270,173
5,207,078 7,613,880
5 5,277 6,881
11 845,946 587,605
10 109,960 117,431
12 40,616 46,679
14 170,413 163,049
1,172,212 921,645
6,379,290 8,535,525
15 294,781 262,400
14 467,352 558,055
4 213,861 187,414
13 25,189 21,395
10 24,041 21,925
4 114,335 120,801
16 328,969 427,565
1,468,528 1,599,555
2022 290
12 31
2022 2021
16 209,148 202,113
4 42,026 220,289
10 34,517 43,041
13 15,996 14,169
4 179,625 269,561
14 46,095 54,234
527,407 803,407
1,995,935 2,402,962
25
0.0001
9,500,000,000 2022 12 31
2021 12 31
1,356,140,180 1,334,804,281 135 133
11,540,979 11,191,007
21 (77,417) 17,950
(7,080,342) (5,076,527)
4,383,355 6,132,563
6,379,290 8,535,525
291 2022
12 31
2022 2021
17 1,254,612 633,987
4 161,309 542,296
1,415,921 1,176,283
286,475 164,906
1,640,508 1,459,239
1,277,852 990,123
12 751 750
3,205,586 2,615,018
(1,789,665) (1,438,735)
52,480 (15,757)
6 (223,852) 15,904
(1,961,037) (1,438,588)
13 42,778 19,228
(2,003,815) (1,457,816)
19 (1.49) (1.21)
19 1,340,729,572 1,206,210,049
(19.43) (15.71)
103,133,044 92,785,388
2022 292
12 31
2022 2021
(2,003,815) (1,457,816)
21 (90,421) 13,714
24 365 1,865
21 (5,311) (4,571)
(2,099,182) (1,446,808)
293 2022
12 31
2022 2021
(2,003,815) (1,457,816)
66,278 46,457
20 303,162 240,712
4 68,665 83,500
4 (96,402) (112,486)
6 21,996 (7,632)
2,059 3,377
9,047 23,510
304,112 (423,019)
(56,689) (153,333)
(3,282) (107,128)
(4,352) 20,008
45,627 140,044
(151,816) 407,703
(1,209) (2,620)
(1,496,619) (1,298,723)
(325,434) (262,942)
(1,485) (2,147,881)
1,563,618 3,146,891
(143,665) (8,500)
12 – (43,409)
6 (15,911) (43,500)
1,077,123 640,659
2022 294
12 31
2022 2021
22 – 3,392,616
22 – 50,000
16 37,372 16,838
16 313,774 406,449
16 (417,081) (321,754)
46,964 92,762
(18,971) 3,636,911
(69,383) 14,035
(507,850) 2,992,882
4,382,887 1,390,005
3,875,037 4,382,887
3,869,564 4,375,678
196 328
5,277 6,881
29,500 15,695
25,169 29,967
95,346 53,197
– 75,000
295 2022
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,618,711) 3,803,281
115,055,260 12 3,392,604 – – 3,392,616
2,151,877 – 50,000 – – 50,000
28,778,893 3 92,759 – – 92,762
(2,003,690) – – – – –
– – 240,712 – – 240,712
– – – 11,008 – 11,008
– – – – (1,457,816) (1,457,816)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (5,076,527) 6,132,563
– – (152) – – (152)
1,375,621 – – – – –
19,960,278 2 46,962 – – 46,964
– – 303,162 – – 303,162
– – – (95,367) – (95,367)
– – – – (2,003,815) (2,003,815)
2022 12 31 1,356,140,180 135 11,540,979 (77,417) (7,080,342) 4,383,355
2022 296
1.
3
(BTK)
PD-1
PARP1 PARP2
13
2,700 50 80
30
3
18,000
CMOs
2010
29 9,000
297 2022
1.
2022 12 31 48
BeiGene 101 – 100%
BeiGene AUS Pty Ltd 56,947,230 100%
BeiGene Australia
BeiGene Austria GmbH 35,000 100%
BeiGene (Beijing) Co., Ltd. * 1,922,787,023 100%
BeiGene Beijing
BeiGene Biologics Co., Ltd. * 14,540,000,000 100%
BeiGene Biologics
BeiGene (Canada) ULC 100 100%
BeiGene ESP, S.L.U. 3,000 100%
BeiGene France Sarl 7,500 100%
* 12,490,389,800 100%
* 263,000,000 100%
BeiGene Germany GmbH 25,000 100%
2022 298
1.
BeiGene (Hong Kong) Co., Limited 1 100%
13,700,000,000
* 4,000,000 100%
BeiGene International GmbH 20,000 100%
BeiGene (Italy) S.r.l. 10,000 100%
BeiGene Brazil Ltda. 2,450,190 100%
BeiGene Poland sp. z o.o. 5,000 100%
BeiGene South Africa Pty Ltd. – 100%
BeiGene Sweden AB 25,000 100%
BeiGene Turkey Medical Products 10,000 100%
Trade Limited Company
BeiGene Ireland Limited – 100%
BeiGene Ireland
BeiGene Japan, Ltd. 1,781,660 100%
BeiGene Korea Y.H. 145,000,000 100%
BeiGene Netherlands B.V. – 100%
BeiGene NZ Unlimited 100,000 100%
BeiGene NZ, Limited
BeiGene Pharmaceuticals GmbH 20,000 100%
299 2022
1.
* 3,800,000 100%
BeiGene Pharmaceuticals Israel Ltd. 10,000 100%
* 7,000,000 100%
* 1,000,000 100%
* 1,434,344,311 100%
* 1,000,000 100%
* 270,000,000 100%
BeiGene Singapore Pte. Ltd. 1 100%
* 3,673,218,389 100%
BeiGene Switzerland GmbH 20,000 100%
BeiGene Switzerland
168,000,000 100%
BeiGene UK, Ltd. BeiGene UK 143 100%
BeiGene United Kingdom, Ltd. 110 100%
BeiGene USA, Inc. BeiGene USA 1 100%
BeiGene US Holdings, LLC 54,000,000 100%
2022 300
1.
BeiGene US Manufacturing Co., Inc. 210,000,000 100%
BeiGene Hopewell Urban Renewal, 125,000,000 100%
LLC
Pi Health, Ltd. 22,500,000 100%
Pi Health USA, LLC 5,000,000 100%
Pi Health Brasil Consultoria Ltda. – 100%
B10 Health Technologies Private 370,344,475 100%
Limited
Newco 101 – 100%
*
2.
2020
MapKure, LLC MapKure
2020 6 MapKure
6 2020 11
9
301 2022
2.
830
2022 302
2.
303 2022
2.
2022 304
2.
305 2022
2.
20
3 10
3 5
3 5
842 842
842-20-25
2022 12 31
2022 306
2.
12
842
2017
2019 2021
50
2018 36
2020 2022
30
307 2022
2.
2022 2021 12 31
10
2022 2021 12 31
2022 308
2.
2022 2021 12 31
820 820
820
820
1
2
3
820 (1) (2) (3)
309 2022
2.
2022 2021 12 31
2022 12 31 1 2 3
758,114
6
665,251
6
3,307 706
3,000
6
5,190
1,426,672 706 8,190
2021 12 31 1 2 3
107,855
315,564
6
2,241,962
6
23,809 10,306
2,689,190 10,306
2022 310
2.
3
Leap Therapeutics, Inc Leap
2020 1 2021 9 Leap
Leap 1 Leap
2
6
3
2022 2021 12 31
606 606
606
606
(i) (ii) (iii)
(iv) (v)
311 2022
2.
606
EUSA Pharma
100%
45 90
2022 312
2.
NRDL
808
808
808
808
606 808
606
313 2022
2.
2022 314
2.
(i) (ii)
(i) (ii)
(iii)
(iv) (v)
315 2022
2.
2022 2021 12 31
2022 316
2.
2022 2021 12 31
38,118,000 44,593,000 2022 12 31
3,169,000
2022 2021 12 31
58,000 1,759,000 2022 12 31
1,664,000
220
317 2022
2.
718 718
718
718
718 505
505-50
2022 318
2.
740
50%
319 2022
2.
260
280
2022 320
2.
2022 2021 12 31 3,869,564,000 4,375,678,000
2022 2021 12 31
665,251,000 2,241,962,000
2022 2021 12 31
2022 2021 12 31 173,168,000 483,113,000
2022 12 31 ASD Specialty
Healthcare 18.1% 15.5% 14.2% 12.1% 2022
12 31 57.0% 2022 12 31
321 2022
2.
2021 12 31
26.0% 19.9% 16.7% 2021 12 31 23.4% 2021
12 31 2021
12 31 66.4% Ociperlimab
300,000,000
2022 322
2.
1994
2005 7 21
2022 2021 12 31
8.2% 2.3%
323 2022
2.
740
2022
2022 10 2022 9 30
2022 324
2.
99 108
2022 12 31 12
2021
3 13 19
2021 11 2021-10 832
2021 12 15
2022 1 1
325 2022
3.
2
2021 2
2021 12 31
110,424 (110,424) –
1,032,069 (110,424) 921,645
8,645,949 (110,424) 8,535,525
(4,966,103) (110,424) (5,076,527)
6,242,987 (110,424) 6,132,563
8,645,949 (110,424) 8,535,525
2021 12 31
(25,234) 44,462 19,228
(1,413,354) (44,462) (1,457,816)
(1.17) (0.04) (1.21)
(15.23) (0.48) (15.71)
2022 326
3.
2021 12 31
(1,413,354) (44,462) (1,457,816)
(1,402,346) (44,462) (1,446,808)
2021 12 31
(1,413,354) (44,462) (1,457,816)
(41,085) 44,462 3,377
(1,298,723) – (1,298,723)
2020 12 31 (3,552,749) (65,962) (3,618,711) 3,869,243 (65,962) 3,803,281
(1,413,354) (44,462) (1,457,816) (1,413,354) (44,462) (1,457,816)
2021 12 31 (4,966,103) (110,424) (5,076,527) 6,242,987 (110,424) 6,132,563
327 2022
4.
2022 12 31
2022 2021 12 31
12 31
2022 2021
– 484,646
46,822 53,671
104,994 3,979
9,493 –
161,309 542,296
2022 328
4.
2021 1
650,000,000
1,300,000,000
250,000,000
606
(1)
(2)
(3)
329 2022
4.
606
650,000,000
484,646,000 165,354,000
2022 330
4.
2021 12 31
2021 12 31
2022 2021 12 31 39,655,000
53,421,000 2022 12 31
9,493,000
2021 12
TIGIT
5
2022
331 2022
4.
2022 1 300,000,000
2023 2023 2023
600,000,000 700,000,000
745,000,000 1,150,000,000
50%
25%
606
(1)
(2) (3)
(4)
2022 332
4.
300,000,000
71,980,000
213,450,000
14,570,000
333 2022
4.
2022 2021 12 31
104,994,000 3,979,000 2022 2021
12 31 7,167,000 250,000
2019 10
2020 1 2
2022 334
4.
XGEVA 2019
2020 11 2020 7
2020 12
B 2021 7
(R/R) 2022 4
CD19 B
1,250,000,000
KRAS G12C LUMAKRAS(sotorasib) AMG 510
AMG 510
HGRAC 2020 2022 AMG510
AMG 510
2023 2 (i) 2023 1
1 2023 8 31 AMG 510 (ii) AMG
510
335 2022
4.
808 100%
2019 10 31
2020 1 2 174.85 15,895,001
20.5%
Anthony Hooper 2020 1 2023 1
2022 4 20
2022 336
4.
132.74
2,109,902,000
601,857,000
2,779,241,000
2,162,407,000 616,834,000
2020 12 31
2020
12 31
2,162,407
616,834
2,779,241
337 2022
4.
2022 2021 12 31
12 31
2022 2021
98,955 115,464
96,402 112,486
195,357 227,950
2022
12 31
595,702
2022 12 31 2021 12 31
12 31
2022 2021
114,335 120,801
179,625 269,561
293,960 390,362
2022 338
4.
2022 2021 12 31
12 31
2022 2021
5,898 1,893
(54,865) (45,152)
(1,216) 423
(50,183) (42,836)
2022 2021 12 31
71,720,000 110,303,000 2022 12 31 2021 12 31
54,064,000 106,790,000
2022 12 31 18.2%
14A
339 2022
4.
2022 2021 12 31
12 31
2022 2021
68,665 83,500
5,500 15,000
– 43,394
74,165 141,894
2022 12
LY01005 2022 12
48,665,000
30,000,000
2022 340
4.
Shoreline Biosciences, Inc.
2021 6 Shoreline Biosciences Inc. Shoreline Shoreline
iPSC
Shoreline
Shoreline Shoreline
Shoreline 2022 1
45,000,000
2021 12
31
2021 12
LBL-007 LAG-3
2022 1 30,000,000
742,000,000
2021 12 31
EUSA Pharma
2020 1 EUSA Pharma EUSA
β EUSA
EUSA
40,000,000 120,000,000
2020 12 31
2021
EUSA
341 2022
4.
Assembly Biosciences, Inc.
2020 7 Assembly Biosciences, Inc Assembly Assembly
Assembly ABI-H0731 ABI-H2158 ABI-H3733
Assembly
Assembly 40,000,000
503,750,000 Assembly
2020
12 31
2020 8
(BAT1706)
2020 9 10 2020 9 18
2020 10 20,000,000
145,000,000
2020 12 31 2021 11
2022 342
4.
2022 2021 12 31
5.
2022 12 31 2021 12 31 5,473,000
7,209,000
343 2022
6.
2022 12 31
674,262 – 9,011 665,251
674,262 – 9,011 665,251
2021 12 31
2,245,662 – 3,700 2,241,962
2,245,662 – 3,700 2,241,962
2022 12 31 2022 12 31
2022 12 31
2022 344
6.
Leap Therapeutics, Inc. (Leap)
2020 1 Leap 5,000,000 Leap B
B 2020 3 Leap Leap
2021 9 Leap 7,250,000
Leap 2022 12 31 Leap
7.4% 11.7%
2022
2021 12 31 30,102,000
9,386,000
2022 12 31 2021 12 31
12 31
2022 2021
Leap 3,307 23,809
Leap 706 10,306
2022 12 31 2021 12 31
57,054,000 43,722,000 2022 12 31
5,065,000
2021 12 31
345 2022
6.
2022 12 31 2021 12 31 27,710,000 22,955,000
2022 2021 12 31 3,682,000 1,796,000
7.
12 31
2022 2021
173,379 483,528
(211) (415)
173,168 483,113
30 120
12 31
2022 2021
6 172,633 483,113
6 12 535 –
173,168 483,113
2022 346
7.
12 31
2022 2021
1 1 415 112
(219) 309
1 –
14 (6)
12 31 211 415
8.
12 31
2022 2021
88,957 78,140
20,886 9,397
172,503 155,089
282,346 242,626
347 2022
9.
(CTA)
(MAA)
2017 3
200,000,000
95%
100,000,000 5% 2017 3 7
900,000,000
2019 9
100%
95%
2022 348
9.
2020 9
5% 28,723,000 195,262,000
2020 11 9,116,000
100%
19,599,000
132,061,000 900,000,000 36,558,000
249,140,000
200,000,000
120,000,000 80,000,000
2020 10
80,000,000 118,320,000 2021
10 9 198,320,000 200,000,000
73,640,000 500,000,000
14,728,000 100,000,000 58,912,000
400,000,000 2021 12 31
15,693,000 100,000,000 2022 11
16
349 2022
10.
50 36 30
12
12 31
2022 2021
25,938 22,536
6,834 4,892
1,299 1,823
34,071 29,251
12 31
2022 2021
56,008 60,762
53,952 56,669
109,960 117,431
24,041 21,925
34,517 43,041
58,558 64,966
2022 350
10.
2023 12 31 26,278
2024 12 31 21,647
2025 12 31 11,312
2026 12 31 2,821
2027 12 31 966
63,024
(4,466)
58,558
12 31
2022 2021
28,064 19,962
22,278 37,454
12 31
2022 2021
3 3
5.76% 5.15%
351 2022
11.
12 31
2022 2021
65,485 65,485
158,908 118,203
53,786 50,288
222,448 144,083
175,679 119,585
47,483 27,404
723,789 525,048
(171,470) (124,286)
293,627 186,843
845,946 587,605
2021 11 75,197,000 42
2022 352
11.
2022 2021 12 31
12 31
2022 2021
224,392 90,229
33,332 63,361
12,256 17,178
23,647 16,075
293,627 186,843
2022 2021 12 31 62,302,000 44,742,000
12.
2022 12 31 2021 12 31
2022 12 31 2021 12 31
7,500 (4,000) 3,500 7,500 (3,250) 4,250
41,235 (4,119) 37,116 43,394 (965) 42,429
816 (816) – 816 (816) –
49,551 (8,935) 40,616 51,710 (5,031) 46,679
353 2022
12.
10
2018 9 2020 2
2024 2
12
12 31
2022 2021
3,225 965
751 750
3,976 1,715
2022 12 31
12 31
2023 3,170 750 3,920
2024 3,170 750 3,920
2025 3,170 750 3,920
2026 3,170 750 3,920
2027 3,170 500 3,670
2028 21,266 – 21,266
37,116 3,500 40,616
2022 354
13.
12 31
2022 2021
(583,610) (606,752)
67,744 34,923
(1,445,171) (866,759)
(1,961,037) (1,438,588)
12 31
2022 2021
27,905 15,252
4,844 (9)
6,547 805
39,296 16,048
3,480 4,919
– (35)
2 (1,704)
3,482 3,180
42,778 19,228
355 2022
13.
12 31
2022 2021
(1,961,037) (1,438,588)
25% 25%
(490,259) (359,647)
288,133 185,874
30,598 (2,826)
33,872 (27,411)
229,550 254,768
(49,116) (31,530)
42,778 19,228
(2.2)% (1.3)%
12 31
2022 2021
97,896 84,766
862,214 625,114
19,700 14,982
86,000 82,060
798,563 937,069
10,348 11,571
63,156 –
(10,098) (11,322)
1,927,779 1,744,240
(1,943,775) (1,758,409)
(15,996) (14,169)
2022 356
13.
2022 12 31
2022 2021 12 31 229,550,000 254,768,000
2022 2021 12 31 5,077,247,000 3,644,981,000
2022 12 31 2024 2032
1,633,101,000 2025 2029 3,397,529,000
26,079,000 108,861,000
2036 2042
2022 2021 12 31
12 31
2022 2021
1 1 9,925 7,123
– –
– –
1,630 2,802
– –
12 31 11,555 9,925
357 2022
13.
2022
12 31 12
2022 2021 12 31
2022
12 31 2013 2022 2012 2022
2018 2022 2015 2022
2012 2022
2025 2022
12 31 3,894,000 0.01
2022 12 31
2,379,000
2022 358
14.
12 31
2022 2021
71,488 87,239
20,478 58,579
22,777 12,010
3,039 5,052
3,664 1,695
58,950 78,538
1,510 2,982
34,647 24,078
216,553 270,173
12 31
2022 2021
109 109
22,025 14,140
(1) 48,642 24,237
804 17,162
7,054 6,609
91,779 100,792
170,413 163,049
(1)
359 2022
14.
12 31
2022 2021
184,775 139,966
139,168 213,922
51,806 71,560
18,815 45,661
41,817 59,639
30,971 27,307
467,352 558,055
12 31
2022 2021
38,176 46,352
7,760 7,814
159 68
46,095 54,234
2022 360
15.
2022 12 31 2021 12 31
12 31
2022 2021
3 290,284 257,977
3 6 2,570 3,210
6 1 1,379 1,110
1 548 103
294,781 262,400
16.
2022 2021 12 31
12 31
2022 2021
2018 4 4 580,000 9 2027 4 4 (1) 7,250 50,000 1,255 8,000
2020 1 22 (2) 9 2029 1 20 (2) 1,450 10,000 1,569 10,000
2020 11 9 378,000 9 2029 11 8 (3) 5,437 37,500 – –
2020 9 24 200,000 (4) 4.3% 150,000 1,034,554 200,000 1,274,535
2020 9 24 500,000 (5) 4.5% – – 15,693 100,000
2022 2 25 50,000 1 2023 2 25 2.2% 50,000 344,851 – –
(6) 114,832 792,000 209,048 1,332,197
328,969 2,268,905 427,565 2,724,732
361 2022
16.
12 31
2022 2021
2018 4 4 580,000 9 2027 4 4 (1) 75,395 520,000 89,444 570,000
2020 1 22 (2) 9 2029 1 20 (2) 49,369 340,500 53,353 340,000
2020 11 9 378,000 9 2029 11 8 (3) 47,847 330,000 59,316 378,000
2022 7 29 480,000 10 2032 7 28 (7) 36,537 252,000 – –
209,148 1,442,500 202,113 1,288,000
1. 2022 12 31 4.7%
2022 12 31 1,171,000 8,000,000
2. 2020 1 22
1,100,000,000
2020 12 31
1,100,000,000 350,000,000
2022 12 31 4.4% 2022 12 31 1,484,000
10,000,000 2017 3 3
3. 2022 12 31 4.0%
4. 2020 9 200,000,000 120,000,000
80,000,000
2021 10 8
2021 10 8 2022 10 8
2022 9 30 2022 10 10
200,000,000 150,000,000
2022 362
16.
5. 2020 9 73,640,000 500,000,000
14,728,000 100,000,000 58,912,000 400,000,000
(i)2021 11 9
(ii) 2021 10 8
(i)2022 11 9
(ii) 2022 10 10 13,980,000
100,000,000 Hillhouse Capital Hillhouse
Capital Hillhouse Capital
6. 2022 12 31
2,435,000,000 2021 1 19 2023 9 18 2022 12 31
113,774,000 792,000,000 2022 12 31
200,446,000 1,332,197,000 2022 12 31
2.6%
7. 2022 7
480,000,000 2022 12 31 4.2%
2022 12 31 37,372,000
252,000,000
2022 12 31
2023 12 31 328,969
2024 12 31 29,412
2025 12 31 35,136
2026 12 31 44,697
2027 12 31 44,697
55,206
538,117
363 2022
16.
2022 2021 12 31
21,699,000 29,263,000 2,594,000 1,054,000
17.
2022 2021 12 31
12 31
2022 2021
1,438,440 748,824
(183,828) (114,837)
1,254,612 633,987
2022 364
17.
2022 2021 12 31
12 31
2022 2021
564,651 217,987
422,885 255,119
79,049 70,065
63,398 45,956
38,124 1,353
36,107 12,515
13,696 –
15,213 19,591
5,460 3,661
16,029 7,740
1,254,612 633,987
2022 2021 12 31
12 31
2022 2021
1 1 59,639 11,874
183,828 114,837
(201,650) (67,072)
12 31 41,817 59,639
365 2022
18.
12 31
2022 2021
286,475 164,906
11 62,302 44,742
1,640,508 1,459,239
10 25,938 22,536
12 3,976 1,715
7,037 3,821
1,000,890 720,551
303,162 240,712
50,358 38,810
1,354,410 1,000,073
233,812 5,991
7 (218) 309
(74,234) (13,528)
44 106
2022 2021 12 31 602,585,000 463,441,000
2022 366
19.
12 31
2022 2021
(2,003,815) (1,457,816)
1,340,729,572 1,206,210,049
(1.49) (1.21)
2022 2021 12 31
2022 2021 12
31
367 2022
20.
2016
2016 1 2016
2016 2016 2 65,029,595 2016
2011 2011 2016
2011
2022 12 31 2011 2016
5,166,653 2016 2017 1 1
(i) (5)% (ii)
2018 1 1 29,603,616
2016 2018 8 2016
2018 12 2016 38,553,159
2020 6 2016
57,200,000 2030 4 13
2016
2022 12 31 2016 75,034,504
2016 2016
2016 66,300,000 2022 3 31
5% 2022 6 22
2022 368
20.
2018
2018 6 2018 2018 12,000,000
5635(c)(4) 5635(c)(4)
2018 2018
2016 2018 8
2018
2016 2018 2022 6 22
2018
2018 6 2018 3,500,000
2018 8
2018 12 3,855,315
7,355,315 6
15%
10%
369 2022
20.
2018
1 2
2022 8 31 861,315 171.66 13.20 145.91 11.22 9,667
2022 2 28 667,160 210.52 16.19 178.94 13.76 9,183
2021 8 31 425,386 308.30 23.72 262.06 20.16 8,575
2021 2 26 436,124 236.30 18.18 200.86 15.45 6,738
2020 8 31 485,069 164.06 12.62 139.45 10.73 5,203
2020 2 28 425,425 145.54 11.20 123.71 9.52 4,048
1
2
2022 12 31 3,666,071
2022 370
20.
10
2011 2016 2018
2020 12 31 84,991,715 5.27
6,244,524 26.46 12.40
(17,233,853) 4.52 367,110
(1,797,498) 13.27
2021 12 31 72,204,888 7.08
12,516,816 12.34 6.40
(5,898,217) 4.63 52,258
(2,296,634) 16.46
2022 12 31 76,526,853 7.85 5.33 745,340,712
2022 12 31 58,017,219 5.67 4.2 673,364,735
2022 12 31 73,842,956 7.60 5.2 734,904,195
371 2022
20.
2022 12 31 15,825,737
88,859,000 2.4
2022 2021 12 31 62,548,000
53,571,000
12 31
2022 2021
5.51 ~ 9.04 9.94 ~ 14.97
1.8% ~ 3.9% 1.1% ~ 1.7%
2.8 2.8
51% ~ 60% 51% ~ 59%
0% 0%
10 10
2022 2021 12 31
2022 12 31
2022 372
20.
2016 2018
2020 12 31 34,876,972 12.50
17,173,767 25.58
(10,703,381) 12.23
(5,264,376) 15.82
2021 12 31 36,082,982 18.33
38,707,669 12.46
(12,533,586) 16.37
(6,859,892) 16.72
2022 12 31 55,397,173 14.87
2022 12 31 47,392,282 14.87
2022 12 31 580,815,000
2.9
2022 2021 12 31
12 31
2022 2021
139,348 114,357
163,814 126,355
303,162 240,712
373 2022
21.
2020 12 31 14,184 871 (8,113) 6,942
13,714 (4,504) 309 9,519
(1)
– (67) 1,556 1,489
13,714 (4,571) 1,865 11,008
2021 12 31 27,898 (3,700) (6,248) 17,950
(90,421) (5,311) (446) (96,178)
(1)
– – 811 811
(90,421) (5,311) 365 (95,367)
2022 12 31 (62,523) (9,011) (5,883) (77,417)
(1)
2022 374
22.
2022 2021 12 31
2019 10 31 2019 12 6 2020 9 24
(SPA) 2021 9
165,529 2,151,877 50,000,000
2021 12
192.60 391.68
115,055,260
3,392,616,000
23.
10%
50%
375 2022
23.
2022 2021 12 31
10%
2022 12 31 2021 12 31
3,548,881,000 760,476,000
24.
2022 2021 12 31
83,860,000 63,772,000
401(k) 401(k) 401(k)
401(k)
2021 4% 2022 12 31 2021 12 31
401(k) 10,298,000 7,483,000
2022 376
24.
2022 2021 12 31 3,887,000
2,986,000
2022 12 31 2021 12 31
45,835,000 34,517,000 38,075,000
26,703,000 14
2023 2,553,000
2022 12 31
2023 68
2024 545
2025 442
2026 260
2027 755
2028 –2032 7,185
9,255
377 2022
25.
2022 12 31 117,293,000 55,346,000
61,947,000 BMS
BMS
2022 12 31 404,914,000
1,250,000,000 2022 12
31 595,702,000
2022
12 31 22,327,000
19,000,000 2022 12 31
16,000,000
2022 378
25.
(CRO)
26.
383(1)(a) (b) (c) (f) 2
2022 2021 12 31
12 31
2022 2021
795 724
910 828
1,120 919
* 17,760 18,703
14 14
19,804 20,464
20,599 21,188
* 26 27
379 2022
26.
2022 2021 12 31
20
(a)
2022 2021 12 31
2022 12 31
Thomas Malley 93 – – 391 – 484
1
39 – – 210 – 249
Donald W. Glazer 74 – – 391 – 465
Michael Goller 77 – – 391 – 468
Ranjeev Krishana 79 – – 391 – 470
85 – – 391 – 476
2
6 – – -190 – -184
Corazon (Corsee) D. Sanders 96 – – 391 – 487
Alessandro Riva 3
71 – – 330 – 401
Margaret Han Dugan 4
77 – – 330 – 407
697 – – 3,026 – 3,723
1. 2022 6 22
2. 2022 1 31
3. Alessandro Riva 2022 2 1
4. Margaret Han Dugan 2022 2 1
2022 380
26.
(a)
2021 12 31
Thomas Malley 89 – – 345 – 434
76 – – 345 – 421
Donald W. Glazer 70 – – 345 – 415
Michael Goller 73 – – 345 – 418
Ranjeev Krishana 76 – – 345 – 421
84 – – 345 – 429
72 – – 396 – 468
Corazon (Corsee) D. Sanders 92 – – 339 – 431
632 – – 2,805 – 3,437
(b)
2022 2021 12 31
2022 2021 12 31
12 31
2022 2021
– –
910 828
1,120 919
14,343 15,553
14 14
16,387 17,314
381 2022
26.
(b)
2022 2021 12 31 Anthony C.
Hooper 2022 2021 12 31
28
2022 12 31
100 – 150 3,989 – 4,239
Anthony C. Hooper 98 – – 391 – 489
198 – 150 4,380 – 4,728
2021 12 31
100 – 150 4,704 – 4,954
Anthony C. Hooper 92 – – 345 – 437
192 – 150 5,049 – 5,391
2022 382
27.
2022 2021 12 31
26
2022 2021
2 2
3 3
5 5
12 31
2022 2021
1,991 1,983
1,433 1,385
18,653 17,646
37 32
22,114 21,046
2022 2021
25,000,001 30,000,000 1 –
35,000,001 40,000,000 – 2
45,000,001 50,000,000 1 –
80,000,001 85,000,000 – 1
100,000,001 105,000,000 1 –
3 3
383 2022
27.
2022 2021 12 31
20
28.
2022 2021 12 31
2022 12 31
(i) 100,000 2021 100,000 (ii)
150,000 2021 150,000 (iii) 471,913 2021 241,839
3,000,000 2021 3,000,000
(iv)83,499 2021 39,000 1,000,000
2021 1,000,000
14A
29.
2022 384
29.
12 31
2022 2021
840,032 517,173
502,626 495,265
73,263 163,845
1,415,921 1,176,283
2022 12 31 2022 12 31
112,916,000
389,710,000 2021 12
31 379,607,000
115,658,000
2022 12 31 48,393,000 24,870,000
2021 12 31
385 2022
30.
2022 12 31
(i) (iii) (iv)
(1,640,508) (14,697) – 471 (1,654,734)
(1,277,852) (19,296) – 366 (1,296,782)
52,480 – – (3,142) 49,338
(1,961,037) (33,993) – (2,305) (1,997,335)
(42,778) – 10,311 – (32,467)
(2,003,815) (33,993) 10,311 (2,305) (2,029,802)
2022 386
30.
2021 12 31
(i) (iii)
(1,459,239) (21,541) – (1,480,780)
(990,123) (27,189) – (1,017,312)
(1,438,588) (48,730) – (1,487,318)
(19,228) 5,253 (11,775) (25,750)
(1,457,816) (43,477) (11,775) (1,513,068)
387 2022
30.
2022 12 31
(i) (iii) (ii) (iv)
109,960 – – (2,305) 107,655
6,379,290 – – (2,305) 6,376,985
11,540,979 33,993 – – 12,056,915
174,049* 307,894* –
(7,080,342) (33,993) – (2,305) (7,598,583)
10,311 – –
(184,360)* (307,894)* –
4,383,355 – – (2,305) 4,381,050
2022 388
30.
2021 12 31
(i) (ii) (iii)
– 5,253 – 110,424 125,744
10,067* – –
8,535,525 15,320 – 110,424 8,661,269
11,191,007 48,730 – 56,237 11,809,005
125,319* 307,894* 79,818*
(5,076,527) (48,730) – (11,775) (5,568,781)
5,253 (307,894)* (13,856)*
(115,252)* – –
6,132,563 15,320 – 110,424 6,258,307
*
389 2022
30.
(i)
2022 12 31
33,993,000 2021 48,730,000
2021 5,253,000
(ii)
2016 2 307,894,000
307,894,000
2022 390
30.
(iii)
2022 12 31
110,424,000
2022 12 31
10,311,000
(iv)
2019 1 1
16
391 2022
30.
(v)
9
2022 12 31
2022 12 31
2022 392
31.
12 31
2022 2021
1,742,320 3,715,170
51 14
548,303 2,044,198
804,471 920,819
3,095,145 6,680,201
914,653 67,434
7,510 6,563
6,328 7,031
1,621,824 543,502
2,550,315 624,530
5,645,460 7,304,731
446,362 292,988
57,316 123,341
114,335 120,801
297,868 247,076
915,881 784,206
393 2022
31.
12 31
2022 2021
179,625 269,561
166,599 118,401
346,224 387,962
1,262,105 1,172,168
0.0001 9,500,000,000
2022 2021 12 31
1,356,140,180 1,334,804,281 135 133
11,540,979 11,191,007
(77,417) 17,950
(7,080,342) (5,076,527)
4,383,355 6,132,563
5,645,460 7,304,731
2022 394
31.
2020 12 31 1,190,821,941 118 7,414,932 6,942 (3,618,711) 3,803,281
115,055,260 12 3,392,604 – – 3,392,616
2,151,877 – 50,000 – – 50,000
28,778,893 3 92,759 – – 92,762
(2,003,690) – – – – –
– – 240,712 – – 240,712
– – – 11,008 – 11,008
– – – – (1,457,816) (1,457,816)
2021 12 31 1,334,804,281 133 11,191,007 17,950 (5,076,527) 6,132,563
– – (152) – – (152)
1,375,621 – – – – –
19,960,278 2 46,962 – – 46,964
– – 303,162 – – 303,162
– – – (95,367) – (95,367)
– – – – (2,003,815) (2,003,815)
2022 12 31 1,356,140,180 135 11,540,979 (77,417) (7,080,342) 4,383,355
395 2022
32.
2022 12 31 2021 12 31
33.
2023 3 29
2022 396
2
2021 2022 2021
2022 3 31 6 30 9 30 12 31
306,626 341,572 387,628 380,095
(443,287) (439,399) (438,357) (468,622)
(435,198) (565,726) (557,556) (445,335)
(435,198) (565,726) (557,556) (445,335)
(0.33) (0.42) (0.41) (0.33)
2021 3 31 6 30 9 30 12 31
605,872 149,992 206,440 213,979
70,167 (474,838) (462,325) (571,739)
55,580 (484,604) (438,114) (590,678)
55,580 (484,604) (438,114) (590,678)
0.05 (0.41) (0.36) (0.48)
0.04 (0.41) (0.36) (0.48)
397 2022
2011 2011 4 15 2015 4 17 2011
2016 2016 1 14 2016
2022 4 29
2018 2018 2021 6 16
2021 9 1
2018 2018 6 6 2018 8 7
2018 2018 2022 6 22
13
ADS
1987 4 7
2019 10 31
2020 1 2
2021 6 16
2021 12 15
2022 398
2010 10 28
2017 1 25
2017 3 3
BeiGene Switzerland GmbH 2017 9 1
BLA
CMO
622
CRO
EMA (European Medicines Agency)
399 2022
EUSA EUSA Pharma
FDA (U.S. Food and Drug Administration)
(General Data Protection Regulation)
(EU)2016/679
1998 11 27
GEM
2022 400
NMPA (National Medical Products Administration)
Novartis Pharma AG
2018 7 30
2022 12 31
sBLA
571
2019 10 31
401 2022
sNDA
15
2022 402
BRAF B-raf
B
BTK
cHL
CLL
Fcγ Fcγ
MCL
NSCLC
PARP ADP DNA
DNA
PD-1 1 T pro-B
PD-L1 PD-L2 PD-1
T
403 2022
RAF RAF BRAF-BRAF
BRAF-CRAF CRAF-CRAF
SLL
T T T
B
TIM-3 T 3 Th1
UC
WM
2022 404